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Abstract 
Redox reactions play an important role in human physiology and pathophysiology. For 
example, oxidative stress and free radical-mediated oxidation of proteins and lipids are 
implicated in several diseases such as Alzheimer’s and Parkinson’s disease. Oxidation 
reactions belong also to the most important phase I metabolism pathways of drugs, which 
can give rise to pharmacologically active or toxic metabolites. The established methods for 
in vitro drug metabolism studies, e.g. methods using hepatocytes, human liver microsomes 
(HLMs), and recombinant enzymes, are relatively time-consuming and expensive. Thus, the 
potential of several nonenzymatic oxidation methods, such as those based on 
metalloporphyrins, electrochemistry (EC), and Fenton reaction, have been explored for 
metabolism studies. However, new methods need to be developed to enable rapid 
production of drug metabolite standards and since none of the above nonenzymatic methods 
allow comprehensive prediction of phase I drug metabolism. 
The titanium dioxide (TiO2) photocatalysis method was developed and applied to 
evaluate the effect of phosphorylation of tyrosine on the oxidation of (phospho)peptides 
with the same sequence but different phosphorylation states. The results obtained using 
ultra-high-performance liquid chromatography – mass spectrometry (UHPLC-MS) show 
that nonphosphorylated tyrosine was the amino acid most susceptible to hydroxyl radical-
initiated oxidation, but oxidation of tyrosine was in most cases inhibited by its 
phosphorylation. 
The feasibility of TiO2 photocatalysis for imitation of in vitro phase I HLM metabolism 
of small drug molecules was studied using UHPLC-MS and compared with the 
electrochemically assisted Fenton reaction (EC-Fenton) and EC. TiO2 photocatalysis, EC-
Fenton, and EC imitated 44%, 31%, and 11%, respectively, of the in vitro phase I HLM 
metabolites of four model compounds. As TiO2 photocatalysis proved most feasible for the 
imitation of in vitro phase I HLM metabolism, its feasibility for imitation of in vitro phase 
I HLM metabolism of five anabolic steroids was also examined. TiO2 photocatalysis was 
able to imitate over half of the hydroxylation and dehydrogenation metabolites, but its 
imitation of the metabolites resulting from combinations of these reactions was considerably 
poorer. 
To enable even more rapid experiments to study biologically relevant oxidation 
reactions, TiO2-photocatalysis was simply integrated with desorption electrospray 
ionization (DESI)-MS by using the same TiO2-coated glass wafer for photocatalytic 
reactions and DESI-MS analysis. This new method enabled high-throughput investigation 
of photocatalytic oxidation reactions, as demonstrated using 12 model compounds, and 
imitation of several drug metabolism reactions of three model compounds studied in more 
detail. 
In conclusion, TiO2 photocatalysis proved a feasible method for oxidation of compounds 
with different polarities. TiO2 photocatalysis cannot predict drug metabolism 
comprehensively, but offers a potential method for rapid, simple, and inexpensive study of 
oxidation reactions of biomolecules and imitation of several drug metabolism reactions. 
Preparative scale synthesis of oxidation products by TiO2 photocatalysis is likely an 
alternative application of the method, but this remains to be demonstrated. 
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1 Introduction 
Redox reactions play a major role in several physiological and pathophysiological processes 
in the human body. For example, oxidative stress and free radical-mediated oxidation of 
biomolecules are implicated in aging and a wide spectrum of diseases, including 
neurodegenerative diseases, such as Parkinson’s and Alzheimer’s disease and amyotrophic 
lateral sclerosis, stroke, central nervous system injuries, cardiovascular diseases, such as 
atherosclerosis, chronic inflammation, diabetes, obesity, and several cancers.[1-5] Oxidation 
reactions are also among the most important phase I metabolism pathways of xenobiotics 
such as drugs[6] and carcinogens[7]. Considering the fundamental role of oxidation reactions 
in human health, it is essential to develop methods for studying and imitating these 
reactions. The work described in this thesis was aimed at developing and applying titanium 
dioxide (TiO2) photocatalytic methods for oxidation of (phospho)peptides, imitation of 
phase I oxidative metabolism, and rapid screening of oxidation products. 
1.1 Oxidative stress and protein oxidation by reactive oxygen 
species 
Reactive oxygen species (ROS) are produced at low levels in normal metabolic processes 
of mammalian cells such as cellular respiration and various enzyme functions.[8] ROS are 
involved as signaling molecules in the regulation of cell proliferation, apoptosis, and gene 
expression.[4, 9] Phagocytes generate ROS as an essential defence mechanism in microbial 
infections. Intensive physical activity, pollutants or toxins, such as cigarette smoke, alcohol, 
and pesticides, ionizing and ultraviolet radiations (UV), and ozone also trigger generation 
of ROS. Transition metal-catalyzed “Fenton-like” reactions are an important source of ROS 
in cells. 
Oxidative stress results from excessive ROS production relative to the cell’s capacity 
for ROS detoxification.[9] ROS include hydroxyl radical (•OH), superoxide anion (O2•−), 
singlet oxygen (1O2), hydrogen peroxide (H2O2), hydroperoxide (HO2•), alkoxyl (RO•) and 
peroxyl (ROO•) radical, ozone (O3), and hypochlorous acid (HOCl).[10] Also reactive 
nitrogen species, such as nitric oxide (NO), nitrogen dioxide (•NO2), and peroxynitrite 
(ONOO-), are involved in oxidative stress. Reactions of ROS often produce other ROS. For 
example, superoxide is the primary ROS created in mitochondrial respiration. It is not very 
reactive towards biological macromolecules. Instead, it reacts with superoxide dismutase to 
produce hydrogen peroxide, which can further react with metal ions or metal complexes to 
form hydroxyl radicals. Hydroxyl radical is the most aggressive oxidant species and 
responsible for most of the oxidative damage of biomolecules.[9] 
Hydroxyl radicals can react with all classes of biomolecules such as lipids, proteins, and 
nucleic acids.[9] Proteins are the most abundant organic components of most biological 
systems[8] and are major initial targets of hydroxyl radicals in the cells.[11] Oxidative damage 
to proteins is mainly irreversible.[2, 8] While some oxidations of cysteine and methionine can 
be reduced enzymatically, mostly the fate of oxidatively damaged proteins is proteolysis.[8] 
Extensive oxidative modifications, cross-linking, and aggregation can render proteins 
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resistant to proteolysis.[12] Proteolysis is also diminished in aging and diseases associated 
with the accumulation of oxidized proteins such as atherosclerosis, cataract, rheumatoid 
arthritis, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. 
Identification of oxidative modifications in vivo is important to find biomarkers possibly 
facilitating diagnosis of diseases. Redox proteomics aims at identification of oxidatively or 
nitrosatively modified proteins.[2] For example, protein carbonylation and tyrosine 
nitrosylation are markers of oxidative stress.  
1.2 Drug metabolism 
Drug metabolism in general facilitates the elimination of drugs from the body. Drug-
metabolizing enzymes are present in all tissues, but the main drug-metabolizing organ is the 
liver.[13] Drug metabolism is often divided into phases I and II. Phase I involves 
functionalization reactions, such as oxidation, reduction, or hydrolysis, where a functional 
group is attached to or exposed in a drug molecule. Phase II involves conjugation reactions 
that facilitate detoxification or excretion of the drug from the body. Phase I metabolism 
plays a key role in the bioactivation of drugs, as phase I reactions may give rise to 
pharmacologically active, toxic, or reactive metabolites.[14, 15] The most important phase I 
metabolic pathways are oxidation reactions catalyzed by cytochrome P450 (CYP450) 
isoenzymes.[16]  
Detailed understanding of the metabolism of a drug candidate is essential at all stages of 
drug discovery and development in view of drug safety and pharmacokinetics.[15, 17] Drug 
metabolism is studied early in the drug discovery phase, as the metabolic stability, major 
metabolites, main metabolism routes, and metabolizing enzymes and their kinetics need to 
be determined before selection of lead and candidate molecules.[17] Drug metabolism is 
preliminary studied in vitro using e.g. liver slices, hepatocytes, complementary DNA-
expressed recombinant enzymes, or subcellular fractions such as human liver microsomes 
(HLMs) or S9 fraction. Whole cell systems, i.e. liver slices and hepatocytes, give the most 
complete view of hepatic metabolism, as all metabolizing enzymes and cofactors are 
present.[18] Thus, the in vitro/in vivo correlation in whole cell systems is superior to that of 
subcellular fractions, and both enzyme induction and inhibition can be studied.[13, 17] In 
addition, hepatocytes and liver slices allow metabolite identification as well as evaluation 
of kinetics and metabolizing enzymes. Subcellular fractions are prepared by differential 
centrifugation of the liver homogenate.[19] The microsomes are vesicles derived from the 
hepatocyte smooth endoplasmatic reticulum and contain the CYP450 enzymes and phase II 
uridine 5'-diphospho-glucuronosyltransferase enzymes, whereas the cytosolic fraction 
contains most phase II enzymes. The S9 fraction contains both the cytosolic and the 
microsomal fractions, thus including both phase I and phase II enzymes. Subcellular 
fractions can be used to identify metabolites and study enzyme kinetics, metabolizing 
enzymes, and enzyme inhibition, but require addition of cofactors.[17] Recombinant 
enzymes allow the study of metabolizing enzymes and enzyme inhibition. Even though the 
well-established in vitro methods yield abundant metabolic information, pharmacokinetic 
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profile and toxicity need to be determined in a rodent and non-rodent animal species before 
clinical studies.[20]  
As drug metabolism is nowadays studied in the early stages of the drug discovery 
process, the number of compounds to be tested is large, producing the need for faster, 
cheaper, and more convenient methods than the traditional in vitro methods, which are 
relatively time-consuming and expensive. In addition, drug metabolites must be produced, 
e.g. for analytical standards and toxicity testing, and can be sometimes difficult to 
synthesize.  
1.3 Oxidation methods for in vitro protein research and imitation 
of drug metabolism 
Oxidation of proteins in vitro allows the study of oxidative modifications and oxidation 
mechanisms in a less complex environment without biological interferences. Oxidation of 
proteins has also been exploited in proteomics, e.g. to facilitate sample preparation and 
purification, to alter chromatographic retention properties, to specifically cleave proteins, 
and to enable protein footprinting.[21] In protein footprinting, protein structure and 
conformational changes are studied by monitoring solvent accessibility.[22] The parts of the 
protein that are exposed to the solvent/environment are modified by reactive species. The 
locations of the oxidized amino acids can be analyzed using liquid chromatography – mass 
spectrometry (LC-MS) and used to determine the tertiary or quaternary structure of the 
protein or the interface region of two interacting proteins.[23]  
As the most important phase I metabolic reactions are oxidation reactions catalyzed by 
CYP450 isoenzymes, various nonenzymatic oxidation methods, such as 
metalloporphyrins,[24] electrochemical reactions,[25, 26] Fenton reaction,[27-29] and TiO2 
photocatalysis[30, 31], have been studied from the perspective of providing faster, more 
convenient, and affordable alternatives to metabolite screening and production in the early 
preclinical phase. Although the exact reaction mechanism may differ from the enzymatic 
route, many CYP450 reactions can be simulated by these methods (Table 1).  
Several methods have been used for oxidation of proteins and drugs, and the following 
sections focus on hydroxyl radical-based oxidation methods, direct electrochemistry (EC), 
and metalloporphyrins, as these are the most relevant considering the scope of this thesis.  
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 Summary of the imitation of the most common phase I drug metabolism reactions 
by Fenton reaction, direct electrochemistry, metalloporphyrins, and TiO2 photocatalysis. 
Reaction Fenton EC Metallo-
porphyrins 
TiO2 
 
x Indirect EC, 
Direct EC: only allylic 
and benzylic 
hydroxylation 
x x 
 
x Indirect EC, 
Direct EC: only 
hydroxylation of 
aromatic rings with 
activating 
substituents 
x x 
 
x x x x 
 
x x x  
 
x x x  
 
x x x x 
 
x Poorly imitated, ipso-
substitution of 
aromatic rings more 
likely 
x x 
Fenton reactions are from refs. [26-29, 32-35]  
Electrochemical reactions are from refs. [25, 26, 36-42]  
Metalloporphyrin reactions are from refs. [26, 43]  
TiO2 photocatalytic reactions are from refs. [30, 31, 44-46]  
 
1.3.1 Hydroxyl radical-based methods 
Hydroxyl radicals can be generated from water or hydrogen peroxide by various chemical, 
photochemical, electrochemical, or electrophysical methods.[21, 22, 47] Even though hydroxyl 
radicals can be regarded as the main oxidative species, also other ROS, such as superoxide, 
hydroperoxide, and hydrogen peroxide, are often formed.[22] 
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In the Fenton reaction,[48] hydrogen peroxide oxidizes Fe2+ to Fe3+ and dissociates to a 
hydroxyl ion and a hydroxyl radical (Equation 1).[49] Active Fe2+ can be regenerated from 
Fe3+ by using a chemical reductive agent, such as ascorbic acid, or electrochemical reduction 
at the working electrode.[50, 51] Several other transition metal ions in their lower oxidation 
states (e.g. Cu+, Ti3+, Cr2+, and Co2+) and their complexes catalyze “Fenton-like” oxidation 
reactions similarly to the Fenton reagents.[22]  
(1) Fe2+ + H2O2 ? Fe3+ + OH• + OH- 
Radiolysis of water and photolysis of hydrogen peroxide generate hydroxyl radicals 
photochemically. Radiolysis of water can be achieved by synchrotron X-ray irradiation,[52, 
53] γ-ray irradiation produced by decay of, for example, 60Co or 137Ce,[11, 54] or pulsed 
electron beams accelerated in a particle accelerator.[55] The specific, expensive equipment, 
which is not widely accessible, and use of ionizing radiation are the disadvantages of the 
radiolytic techniques. UV-induced homolysis of hydrogen peroxide in an aqueous solution 
generates two hydroxyl radicals.[56] The advantage of photochemical methods is fast (nano- 
to microseconds) radical generation, which allows time-resolved protein footprinting.[47, 55]  
Water can be oxidized in an electrochemical cell to hydroxyl radicals at sufficiently high 
potentials.[21] A high voltage (typically 6-8 kV) on the electrospray emitter tip of an ordinary 
electrospray ion source of a mass spectrometer can generate a corona discharge, which leads 
to formation of hydroxyl radicals and other ROS, which can react with proteins in the gas 
phase.[57] Oxygen can be used as a nebulizer gas to enhance formation of ROS.  
Hydroxyl radicals react with organic molecules by hydrogen atom abstraction from 
saturated carbons or by addition to unsaturated bonds or aromatic rings.[22] Even though the 
hydroxyl radicals are relatively non-selective oxidants, the selectivity of their reactions is 
determined by several factors: the strength of the C-H bond, the electronegativity of the 
substituents on the target sites, the stability of the nascent organoradical, steric effects, and 
statistical factors (i.e. the number of equivalent positions of attack).[8, 22]  
As proteins are the primary target of hydroxyl radicals in oxidative stress, oxidation of 
proteins, peptides, and amino acids by hydroxyl radicals has been widely studied.[11, 58-61] 
Hydroxyl radicals provide also an excellent tool for protein footprinting and enable 
investigations of protein structure, folding/unfolding, interactions, aggregation, and onset 
of oxidative damage.[47, 53, 56, 62-64] Hydroxyl radicals are able to oxidize both the backbone 
and the side chains of proteins, but the amino acid residues are usually more accessible than 
the backbone.[22] Cysteine and methionine are the amino acids most susceptible to hydroxyl 
radical attack, followed by the aromatic tryptophan, tyrosine, and phenylalanine.[8, 22, 58] 
The hydroxyl radical-based Fenton reaction has sporadically been used for imitation of 
drug metabolism. Fenton reaction products of various compounds have been compared with 
the metabolites of these compounds reported in the literature.[27-29, 32-35] Fenton reaction was 
observed to imitate several metabolites resulting from, for instance, aliphatic, aromatic, and 
benzylic hydroxylation, dehydrogenation, N-dealkylation, S-oxidation, defluorination, and 
decarboxylation, and combinations of these (Table 1). Electrochemically assisted Fenton 
reaction (EC-Fenton) has been shown to imitate hydroxylation, dehydrogenation, and 
heteroatom oxidation and dealkylation metabolic reactions.[26] Detailed experimental 
comparisons of metabolic and Fenton reaction product profiles remain nevertheless 
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scarce.[26] Formation of reactive quinone metabolites and intermediate semiquinones of 
paracetamol,[65] amodiaquine,[66] and pyronaridine[67] have also been studied by electron 
pulse radiolysis. 
1.3.2 Direct electrochemical oxidation 
Direct electrochemical oxidation is initiated by electron abstraction from the substrate by 
the electrode, and thus, requires the presence of a non-binding electron that can be initially 
abstracted.[68] Therefore, the sulphur-containing cysteine and methionine, and aromatic 
tryptophan and tyrosine are the amino acids most susceptible to direct electrochemical 
oxidation.[21] Oxidation of cysteine and methionine is reversible, whereas oxidative 
modifications in tryptophan and tyrosine are irreversible. Electrochemical oxidation of 
tyrosine and tryptophan leads to protein cleavage at the C-terminal side of tyrosine and 
tryptophan.[69, 70] This has been suggested as an alternative to the traditional chemical and 
enzymatic cleavage methods, which cleave the proteins at specific amino acid residues. 
Enzymatic protein digestion methods are commonly used in bottom-up proteomics, where 
proteins are cleaved into smaller peptides for identification and characterization by MS.[71] 
Interestingly, it was observed that phosphorylation of tyrosine prevents its 
electrochemical oxidation, inhibiting also the subsequent cleavage.[69] This has been 
exploited as an alternative way to distinquish between phosphorylated and 
unphosphorylated tyrosine residues in peptides.[72, 73] Identification of phosphorylation sites 
is a crucial task in phosphoproteomics.[71] Reversible phosphorylation of tyrosine, 
threonine, and serine is among the most important mechanisms in cell signaling.[74] 
Phosphorylation of tyrosine residues is involved in the regulation of various cellular 
processes such as proliferation, differentiation, cell cycle progression, cell adhesion, and 
metabolic homeostasis. Even though both phosphorylation and oxidation of proteins are 
well known, the effect of phosphorylation on oxidation of proteins and peptides has not 
been studied with methods involving biologically relevant ROS as oxidant species. Namely, 
the electron transfer mechanism of electrochemical oxidation may not be the most 
biologically relevant.  
Imitation of the most important drug metabolism reactions and the compounds studied 
by direct EC have been reviewed recently.[68] In brief, direct EC has proved suitable for 
imitation of drug metabolism reactions that can begin with a single electron transfer 
mechanism, reactions such as dehydrogenation, S-oxidation, P-oxidation, and N-
dealkylation (Table 1).[25] In addition, allylic,[36] benzylic,[26, 41] or aromatic hydroxylation[38, 
40] as well as ipso-substitution[39, 42] can occur in EC if there is an activating electron-
donating heteroatom substituent at a suitable position, enabling initial electron transfer 
followed by electron delocalization to the above-mentioned positions.[68] However, 
overoxidation is common in hydroxylation of substituted aromatic rings, as the 
hydroxylation products may be oxidized further at lower potentials than the starting 
compound.[25] 
Even though, in principle, electrons can be abstracted from any bond, oxidation 
potentials of aliphatic hydrocarbons are typically higher than those of solvents.[75] Thus, 
aliphatic hydroxylation, aromatic hydroxylation of non-activated aromatic rings, and O-
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dealkylation are not observed in direct electrochemistry.[25] However, aliphatic 
hydroxylation and aromatic hydroxylation reactions have been exceptionally achieved with 
use of a platinum electrode and 1.5–2 V potentials.[36, 37] The reaction is not direct EC, but 
is likely mediated by water oxidation (see Section 1.3.1 Hydroxyl radical-based 
methods).[37, 68] O-dealkylation was not achieved for 7-ethoxycoumarin,[25] but was reported 
for verapamil[41], metoprolol,[26] and toremifen[76] The mechanism was not discussed, 
however, and for verapamil and toremifen could actually be ipso-substitution. 
Electrochemical oxidation has resulted in product profiles very similar to those of in vivo 
and in vitro metabolism,[36] but also considerable differences have been reported.[26, 77] 
1.3.3 Metalloporphyrins 
Metalloporphyrins are metalloorganic complexes that act as surrogates for the active centers 
of CYP450 enzymes.[24] Metalloporphyrins have been widely used as biomimetic catalysts 
and for drug metabolism imitation. Whereas molecular oxygen is the oxygen donor in 
CYP450-catalyzed reactions,[78] single oxygen donors, such as peroxides, periodates, and 
iodosylbenzene, are used to provide the oxygen in metalloporphyrin reactions.[24] Iron and 
manganese are the most commonly used metals in metalloporphyrins. Different oxidants, 
solvents, and co-catalysts can be used to control the reaction. 
Metalloporphyrins have been shown to be capable of imitating all of the common types 
of phase I drug metabolism reactions, including aliphatic, benzylic, and aromatic 
hydroxylation, N-dealkylation, O-dealkylation, N-oxidation, S-oxidation, and 
dehydrogenation (Table 1).[26] It is rare, however, that all of the main metabolites of a given 
drug could be imitated by metalloporphyrins.[79, 80] Comprehensive imitation of the 
metabolites of a selected drug may require using several different metalloporphyrin 
catalysts and reaction conditions.[81] The yields of the desired products can be low and 
byproducts, which are not observed in CYP450-mediated metabolism reactions, are often 
observed due to the different selectivities of metalloporphyrins and CYP450 reactions.[82-87] 
Controlling the orientation of the substrate respective to the metalloporphyrin may 
necessitate addition of binding groups to the substrate, especially in the oxidation of 
steroids.[88-91] Metalloporphyrins are strong oxidizing agents and easily oxidizable 
substrates can be overoxidized to stable products, thus bypassing possible reactive 
intermediates formed in phase I metabolism reactions.[24] However, careful selection and 
controlling of reaction conditions may also allow isolation of unstable metabolites or 
intermediates, which may not be observed in metabolism assays.[92] The production of the 
desired product in adequate amounts requires rigorous optimization of the reaction 
conditions such as selection of suitable metalloporphyrin and oxygen donor.[85] Nonetheless, 
even commercial kits for biomimetic production of drug metabolites are available.[93] 
Various reaction conditions are screened and then the reaction conditions are optimized for 
production of the desired metabolite.  
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1.4 Titanium dioxide photocatalysis 
TiO2 can catalyze both oxidation and reduction reactions when exposed to UV, which has 
higher energy than the band gap of TiO2.[94] TiO2 has three mineral forms: anatase, rutile, 
and brookite. Anatase and rutile are the most commonly used in photocatalysis and have 
band gaps of 3.2 eV (385 nm) and 3.0 eV (410 nm), respectively. Anatase is considered 
photocatalytically more active than rutile.[95-97] Commercial Degussa P25 TiO2 is a mixture 
of anatase and rutile and exhibits higher photocatalytic activity than either anatase or rutile 
alone.[98]  
UV excites electrons (e-) from the valence band to the conduction band of TiO2 , leaving 
holes (h+) on the valence band (Figure 1).[99] The formed electron–hole pair separates into a 
free electron and a free hole, which can diffuse to the surface of the TiO2 particle. Surface-
trapped holes can react with water to produce hydroxyl radicals or accept an electron 
directly from an organic molecule adsorbed onto the TiO2 surface. Surface-trapped electrons 
can reduce molecular oxygen to superoxide. In addition, singlet oxygen can be formed by 
oxidation of superoxide by holes.[100, 101] However, singlet oxygen has a lifetime of 2 μs, 
and thus, is likely to participate in photocatalytic oxidation only if the molecule is adsorbed 
on the TiO2 surface.[102, 103]  
 
 
Figure 1 The principle of TiO2 photocatalysis (modified from [99, 104, 105]). 
The TiO2 surface contains amphoteric titanol (TiOH) groups, and the point of zero 
charge of commercial Degussa P25 is 6.25.[105] Above pH 6.25, the TiOH groups 
deprotonate and the surface is negatively charged, whereas below pH 6.25, the TiOH groups 
protonate, making the surface charge positive. The enrichment of phosphopeptides using 
TiO2 columns is based on this,[106-108] and pH control may be relevant also in photocatalytic 
oxidation experiments, even though inconsistent results of the effect of pH and adsorption 
of the substrate have been reported.[109-112] 
TiO2 photocatalysis has been widely applied to degradation of organic pollutants, waste 
water purification and self-cleaning materials.[94, 99, 104] In relation to oxidation of peptides 
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and proteins, TiO2 photocatalysis has been proposed as an alternative protein and peptide 
digestion method[113] and used to study the byproducts of toxic microcystin peptides 
produced by cyanobacteria.[114, 115] As TiO2 photocatalysis generates the same ROS as in 
biological systems, it provides a potential method for imitation of biological oxidation 
reactions in a pure matrix, free from biological interferences.  
Previously, few studies have addressed the use of TiO2 photocatalysis in imitation of 
drug metabolism,[30, 31, 44-46] and no experimental comparisons with other methods (such as 
EC and EC-Fenton) have been reported. TiO2 photocatalysis was reported to be capable of 
hydroxylation, dehydrogenation, and N- and O-dealkylation, forming products similar to 
the metabolites formed in vivo and/or in vitro (Table 1).[30, 31, 44-46] The possible reaction 
mechanisms in TiO2 photocatalysis, namely electron transfer on the TiO2 surface or 
hydroxyl radical attack, should enable imitation of metabolism reactions beginning with 
electron transfer or hydrogen atom transfer mechanisms. 
TiO2 photocatalysis can be conventionally performed using micro- or nano-sized TiO2 
particles. However, the TiO2 particles need to be removed before the analysis, which is time-
consuming and can be difficult to assess by visual inspection in the case of micro- and 
nanoparticles. Performing photocatalysis on a TiO2-coated surface eliminates this 
shortcoming. Photocatalytic coatings have been widely used in self-cleaning and 
antifogging materials such as windows and mirrors.[99] TiO2 coating has also been utilized 
in a microchip that combined a TiO2-coated nanoreactor and micropillar electrospray 
ionization (μPESI).[31] The microchip approach provided much faster analysis of 
photocatalytic reactions than conventional methods. However, the lack of separation of the 
possible reaction products is a disadvantage of this microchip. Furthermore, the fabrication 
of the μPESI chip is demanding and requires the use of expensive clean-room facilities.  
1.5 Mass spectrometry in identification of reaction products 
Reliable identification of reaction products requires specific and sensitive analytical 
methods. LC-MS offers excellent sensitivity and specificity and relatively high sample 
throughput for identification of unknown compounds. Since the invention of atmospheric 
ionization methods, LC-MS has become the preferred technique in drug metabolism and 
proteomics studies.[71, 116-118] The atmospheric ionization methods, electrospray ionization 
(ESI), atmospheric pressure chemical ionization, and atmospheric pressure photoionization, 
enable efficient ionization of different types of molecules and straightforward coupling of 
reversed phase LC to MS.[116, 117] ESI is a very soft ionization method, which also allows 
ionization of proteins and peptides as well as labile conjugates potentially formed in phase 
II metabolism.[116, 119] Ultra-high-performance LC (UHPLC) provides improved 
chromatographic resolution and decreased analysis time owing to the reduced particle size 
of stationary phases in UHPLC columns.[117] 
Minimal sample preparation is preferred to avoid losing reaction products in 
pretreatment or causing conformation changes of proteins. For example, protein 
precipitation to stop the microsomal incubation is an adequate pretreatment in metabolite 
screening. Proteins can be analyzed as intact (top-down proteomics) or can be digested to 
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peptides prior to analysis (bottom-up proteomics).[71, 119] Reaction products are usually 
identified by comparing a test sample with a negative control (blank sample). Anticipated 
reaction products can be searched based on the change in the mass-to-charge ratio (m/z) 
(Table 2).[120] Various data mining tools, metabolite identification software, and protein 
sequence databases are used for identification of the reaction products.[117-120]  
 
 Examples of common phase I drug metabolism and protein oxidation reactions. 
 Reaction Change in 
formula 
Δm/z 
Phase I drug 
metabolism 
reactions[117] 
Hydroxylation or heteroatom oxidation +O +16 
Hydroxylation+dehydrogenation (ketone formation) +O-2H +14 
Dehydrogenation -2H - 2 
Demethylation -CH2 -14 
Dihydroxylation  +2O +32 
Protein 
oxidation 
reactions[22] 
Hydroxylation or methionine oxidation to sulfoxide +O +16 
Dihydroxylation, peroxidation, cysteine oxidation to 
sulfinic acid or methionine oxidation to sulfone  
+2O +32 
Trihydroxylation or cysteine oxidation to sulfonic acid +3O +48 
Hydroxylation+dehydrogenation (carbonylation) +O-2H +14 
Arginine deguanidination +O-CH5N3 -43 
Glutamic or aspartic acid decarboxylation -CH2O -30 
 
 
High-resolution mass spectrometry 
 
High-resolution mass spectrometry (HRMS) instruments, such as time-of-flight (TOF)-MS, 
orbitrap, and Fourier-transform ion synchrotron resonance, allow accurate mass 
measurement and high resolving power, i.e. the capacity to distinquish ions with close m/z 
values, enabling characterization and structural elucidation of unknown compounds.[121, 122] 
The elemental composition of an unknown compound can be calculated based on the 
accurate mass.[121] Mass accuracy is the difference between the theoretical (exact) and 
measured (accurate) mass of an ion. The higher the mass accuracy is, the fewer options of 
elemental compositions exist. High resolving power and the isotopic pattern fit increase 
certainty of the elemental composition calculation.[123] While HRMS allows distinguishing 
isobaric compounds, i.e. compounds with the same nominal mass but different exact masses, 
tandem mass spectrometry (MS/MS) is needed for distinguishing isomeric compounds, i.e. 
compounds having the same number of each isotopic atom but differing in their positions 
within the molecule.  
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Tandem mass spectrometry  
 
MS/MS techniques provide structural information. Precursor ion and neutral loss scan 
modes of triple quadrupole instruments enable group-specific detection of unknown 
metabolites of a drug such as glucuronide or sulfate conjugates.[116, 117] In contrast, product 
ion scan is more powerful in structural characterization of the detected reaction products.[116] 
Determination of elemental compositions of product ions with exact mass measurements 
using HRMS instrument increases the certainty of structural characterization.[117] Typical 
hybrid instruments, which allow reproducible MS/MS with high resolution, have a 
quadrupole (Q) or an ion trap in front of HRMS, e.g. Q-TOF or ion trap-orbitrap.[120] MSn 
experiments with an ion trap mass spectrometer enable more specific elucidation of the sites 
of modification, as the product ions can be selectively isolated and further fragmented.[116]  
The N-terminal protein or peptide fragments are called a-, b-, and c-series and the C-
terminal fragments x-, y-, and z-series, depending on the location of the bond cleavage.[71] 
The b- and y-series ions are most frequently observed ion types in low-energy collisions.[124] 
The amino acid sequence of the peptide and the sites of oxidative modifications can be 
deduced from the mass differences of fragment peaks observed in the product ion spectrum. 
 
 
Ambient mass spectrometry  
 
Ambient MS comprises methods enabling desorption and ionization of compounds directly 
on sample surfaces. The major advantage of these techniques is rapid analysis of the surfaces 
of native objects without the need for sample preparation.[125, 126] Thus, rapid screening and 
fingerprinting are major uses of these techniques, which can also be used in the field 
environment. A multitude of methods have been developed and examples include 
desorption electrospray ionization (DESI),[127] direct analysis in real time,[126] and 
desorption atmospheric photoionization.[128] DESI was used in this work for the sampling 
and ionization of photocatalytic oxidation products directly from a TiO2-coated glass wafer.  
In DESI, a pneumatically assisted charged spray is used to desorb and ionize compounds 
from a surface.[127] The solvent is sprayed from a small capillary with the aid of a nebulizer 
gas, typically nitrogen. Like in ESI, a potential difference of 1-8 kV is applied between the 
spray capillary and the mass spectrometer inlet. Desorption and ionization occur in a single 
step, likely by a droplet pick-up mechanism.[129-131] The spray droplets hit the sample, 
spreading out on the surface to form a thin liquid film, which then dissolves sample 
molecules. Later-arriving droplets remove the sample molecules from the surface. After 
desorption, the ionization proceeds as in ESI.[127] Multiple droplet fissions lead to formation 
of gas-phase analytes by ion evaporation[132, 133] or charge residue mechanisms,[134] and the 
ions are drawn into the mass spectrometer. Like ESI, DESI is best suited for ionic and polar 
compounds. 
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2 Aims of the study 
Oxidative stress and ROS play an important role in several diseases. Therefore, it is 
important to develop methods to study ROS-mediated oxidation of biomolecules, as this 
can be difficult to investigate in the real biological environment. Radiolytic and photolytic 
methods used for the hydroxyl radical-based oxidation of proteins require the use of special 
equipment and/or ionizing radiation. TiO2 photocatalysis may offer a more convenient way 
to oxidize biomolecules. In addition, the effect of tyrosine phosphorylation on oxidation of 
proteins, peptides, or amino acids has not been investigated by an oxidation method, where 
the oxidation is mediated by biologically relevant oxidant species, as in TiO2 photocatalysis. 
Therefore, this study aimed at developing a TiO2 photocatalytic method for oxidation of 
phosphopeptides and at applying it to examine the effect of phosphorylation on the oxidation 
of peptides using UHPLC-MS/MS for the analysis of reaction products (I). 
Rapid, easy, and affordable methods are needed for screening and production of drug 
metabolites. Metalloporphyrins, EC, and Fenton reaction have not been able to imitate the 
oxidative phase I metabolism reactions adequately to allow comprehensive prediction of 
potential drug metabolites. A few studies have suggested that TiO2 photocatalysis is a 
feasible method for drug metabolism imitation. However, the feasibility of TiO2 
photocatalysis for drug metabolism imitation has rarely been critically evaluated by 
comparing the photocatalytic reaction products with the actual metabolites using a proper 
UHPLC-MS/MS method that allows separation of potential isomeric products. 
Furthermore, experimental comparisons with other non-enzymatic oxidation reactions are 
completely lacking. To address this need, this work aimed at comparing the feasibilities of 
TiO2 photocatalysis, EC, and EC-Fenton for imitation of phase I metabolism of drugs (II) 
and at evaluating the feasibility of TiO2 photocatalysis for imitation of phase I metabolism 
of anabolic steroids (III) using UHPLC-MS/MS for the characterization of the reaction 
products. To enhance the applicability of TiO2 photocatalysis for high-throughput screening 
of oxidation products, the aim was to develop a rapid and simple method for photocatalytic 
oxidation and mass spectrometric characterization of oxidation products by integrating TiO2 
photocatalysis with DESI-MS analysis (IV). 
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3 Experimental 
This section briefly describes the chemicals, materials, samples, instrumentation, and 
experimental setups used in the work. Details can be found in original publications I-IV. 
3.1 Chemicals and materials 
Chemicals and materials used in the work are listed in Table 3. Notes indicate their use. The 
solvents were at least HPLC grade, and all reagents were at least reagent grade. Table 4 
presents the model compounds used in this work. 
  
 Chemicals and materials used in the study. 
Chemical/Material Manufacturer/Supplier Use Publication 
Acetonitrile (ACN), LC-MS grade Sigma-Aldrich (Steinheim, 
Germany) 
Solvent II-IV 
Acetonitrile, HPLC grade Biosolve BV (Valkenswaard, 
The Netherlands) 
Solvent II 
Ammonium acetate Sigma-Aldrich (Steinheim, 
Germany) 
Reagent II, III 
Ammonium hydroxide Mallinckrodt Baker B.V. 
(Denventer, The Netherlands) 
Reagent I 
Androstenedione Steraloids (Newport, RI, USA) Standard III 
β-nicotinamide adenine 
dinucleotide 2′-phosphate 
reduced tetrasodium salt 
hydrate (NADPH) 
Sigma-Aldrich (Steinheim, 
Germany) 
Cosubstrate II, III 
Deionized water Milli-Q Plus purification 
system (Molsheim, France), 
Arium® 611 (Sartorius Stedim 
Biotech Gmbh, Goettingen, 
Germany), and 
Millipore Elix® Essential 5 
(Molsheim, France) 
Solvent 
 
Solvent 
 
 
Reagent 
I-IV 
 
II 
 
 
IV 
Disodium hydrogen phosphate Merck (Darmstadt, Germany) Reagent II, III 
Ethylenediaminetetraacetic acid 
disodium salt dehydrate (EDTA, 
99-101%) 
Sigma-Aldrich (Steinheim, 
Germany) 
Reagent II 
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Table 3 continued  Chemicals and materials used in the study. 
Chemical/Material Manufacturer/Supplier Use Publication 
Ferric chloride hexahydrate 
(98%) 
Sigma-Aldrich (Steinheim, 
Germany) 
Reagent II 
Formic acid (98-100%) Sigma-Aldrich (Steinheim, 
Germany) 
Reagent I, II, IV 
Glacial acetic acid (≥ 99.85%) Sigma-Aldrich (Steinheim, 
Germany) 
Modifier II, III 
Human liver microsomes BD Gentest (Franklin Lakes, 
NJ, USA) 
Reagent II, III 
Magnesium chloride Merck (Darmstadt, Germany) Reagent III 
Magnesium chloride 
hexahydrate 
Sigma-Aldrich (Steinheim, 
Germany) 
Reagent II 
Methanol, LC-MS grade 
 
Sigma-Aldrich (Steinheim, 
Germany) 
Solvent I-IV 
Methanol, HPLC grade Biosolve BV (Valkenswaard, 
The Netherlands) 
Solvent II 
Oasis 30 mg 1 mL cartridges Waters (Manchester, UK) Solid phase 
extraction 
III 
Perchloric acid (70-72%) Merck (Darmstadt, Germany) Reagent III 
Pyrex glass wafer (diameter 100 
mm, thickness 0.5 mm) 
Plan Optik AG (Elsoff, 
Germany) 
Sample 
platform 
IV 
Sodium dihydrogen phosphate Sigma-Aldrich (Steinheim, 
Germany) 
Reagent II, III 
Sodium hydroxide Merck (Darmstadt, Germany) Reagent II, III 
Titanium(IV) isopropoxide (TTIP) 
97% 
Aldrich (Steinheim, Germany) Reagent IV 
TiO2 Degussa P-25 Sigma-Aldrich (Steinheim, 
Germany) 
Photocatalyst I-III 
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 Model compounds used in this work. 
Compound Formula Mmonoisotope  Manufacturer/ 
Supplier 
Publication 
(Phospho)peptides (Insulin receptor peptide 1142-1153)   
TRDIYETDYYRK (IR0) C72H107N19O24 1621.77 Anaspec  I 
TRDIpYETDYYRK (IR1A) C72H108N19O27P 1701.74 Anaspec  I 
TRDIYETDpYYRK (IR1B) C72H108N19O27P 1701.74 Anaspec  I 
TRDIYETDYpYRK (IR1C) C72H108N19O27P 1701.74 Anaspec  I 
TRDIpYETDpYpYRK 
(IR3) 
C72H110N19O33P3 1861.67 Anaspec  I 
Small drug molecules and anabolic steroids   
7-ethoxycoumarin C11H10O3 190.0630 Sigma-Aldrich  II 
Amodiaquine 
dihydrochloride dihydrate 
C20H22ClN3O  
(free base) 
355.1451 Sigma-Aldrich  IV 
D-amphetamine sulfate C9H13N  
(free base) 
135.1048 Synthesized in 
house 
IV 
Atenolol C14H22N2O3 266.1630 Sigma-Aldrich  IV 
Buspirone hydrochloride C21H31N5O2  
(free base) 
385.2478 Sigma-Aldrich  II, IV 
Lidocaine hydrochloride 
monohydrate 
C14H22N2O  
(free base) 
234.1810 Sigma-Aldrich  IV 
Metandienone C20H28O2 300.2089 Steraloids  III 
Methyltestosterone C20H30O2 302.2246 Diosynth  III 
Metoprolol tartrate C15H25NO3 267.1834 Sigma-Aldrich  IV 
Moperone hydrochloride C22H26FNO2  
(free base) 
355.1948 Sigma-Aldrich  IV 
Nadolol C17H27NO4 309.1940 Sigma-Aldrich  IV 
Nandrolone  C18H26O2 274.1933 Diosynth  III 
Nicotine hydrogen tartrate C10H14N2  
(free base) 
162.1157 Sigma-Aldrich  IV 
Quinidine sulfate 
dihydrate 
C20H24N2O2  
(free base) 
324.2838 Sigma-Aldrich  IV 
Stanozolol  C21H32N2O 328.2515 Sterling-Winthorp  III 
Promazine hydrochloride C17H20N2S  
(free base) 
284.1347 Sigma-Aldrich 
and Orion  
II 
Propranolol hydrochloride C16H21NO2  
(free base) 
259.1572 Sigma-Aldrich  IV 
Testosterone  C19H28O2 288.2089 Sigma-Aldrich  II, III 
Verapamil hydrochloride C27H38N2O4  
(free base) 
454.2832 Sigma-Aldrich  IV 
T threonine, R arginine, D aspartic acid, I isoleucine, Y tyrosine, E glutamic acid, K lysine, p phosphorylated 
Anaspec (Fremont, CA, USA), Sigma-Aldrich (Steinheim, Germany), Steraloids (Newport, RI, USA), 
Diosynth (Oss, The Netherlands), Orion (Orion Oy, Espoo, Finland) 
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3.2 Sample preparation 
3.2.1 Titanium dioxide photocatalysis 
 
Nanoparticle-based titanium dioxide photocatalysis 
 
Photocatalytic reactions of (phospho)peptides (I), small drug and drug-like molecules (II), 
and anabolic steroids (III) were performed in duplicate using Degussa P25 TiO2 
nanoparticles. Blank samples were prepared without the substrate. The samples were 
magnetically stirred while exposed from above to a 5000-PC Series Dymax UV Curing 
Flood Lamp (Dymax Light Curing Systems, Torrington, CT, USA). The lamp was a metal 
halide UV lamp with nominal intensity of 225 mW cm-2. The photocatalytic protocols for 
oxidation of (phospho)peptides, anabolic steroids, and drugs as well as for evaluation of  the 
effect of acetonitrile on the photocatalytic reaction kinetics and routes are described in Table 
5.  
 
 
Titanium dioxide photocatalysis integrated with desorption electrospray ionization – 
mass spectrometry 
 
The TiO2-coated wafers were fabricated by depositing TiO2 films on Pyrex glass wafers by 
atomic layer deposition (ALD) from TTIP and deionized water at a temperature of 250°C 
with PicosunTM R-150 ALD reactor (Picosun Oy, Espoo, Finland). TTIP was evaporated 
from a heated source and water from an external vessel, held at 60°C and at room 
temperature, respectively. Reactor pressure was in the order of 5 mbar, maintained by mass 
flow controlled, constant nitrogen (99.999% N2) flow and Adixen 2033 C2 vacuum pump 
(Adixen Vacuum Products, Annecy, France). Deposition sequence of 1.6 s TTIP pulse, 5 s 
purge, 0.1 s water pulse, and 5 s purge was repeated for 4000 cycles. The TiO2 films were 
characterized by UV-VIS reflectometry (Hitachi U-2000, Hitachi Ltd., Tokyo, Japan) and 
X-ray diffraction (PANalytical X’Pet Pro, Cu K? radiation, PANalytical B.V., Almelo, The 
Netherlands). 
Aqueous samples (1 μL) of the model drug compounds (50 μM or 100 μM) were 
dispensed on the rim of the TiO2-coated wafer. The diameter of a sample spot was about 2.5 
mm and the sample spots were about 1 mm apart from each other. The sample spots were 
UV exposed (for 15-180 s) from above either online or offline. The UV-exposed droplets 
were allowed to evaporate before DESI-MS analysis.  
Offline reactions were performed using a 5000-PC Series Dymax UV Curing Flood 
Lamp with a metal halide lamp. The whole TiO2-coated wafer was placed under the UV 
lamp (distance approximately 15 cm). For online reactions, a UV lamp (TEK-Lite, Union 
Bridge, MD, USA, maximum at peak 365 nm, intensity of 100 mW cm-2) was positioned 
3.5 mm above the sample wafer. The samples were UV exposed while the TiO2-coated 
wafer rotated and transferred the exposed samples online to DESI-MS analysis. 
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3.2.2 Incubation of human liver microsomes 
The phase I metabolism reactions of buspirone, promazine, testosterone, and 7-
ethoxycoumarin (II) as well as metandienone, methyltestosterone, nandrolone, stanozolol, 
and testosterone (III) were performed in vitro with HLMs (Table 6).  
 
 Human liver microsomal incubation protocols. 
 Drugs (II) Anabolic steroids (III) 
Total volume 100 μL 100 μL 
Phosphate buffer 
concentration (pH 7.4) 
50 mM 50 mM 
Substrate 
concentration 
50 μM 50 μM 
Substrate solvent water (buspirone and 
promazine), water–acetonitrile 
(testosterone and 7-
ethoxycoumarin) 
acetonitrile (testosterone, 
methyltestosterone, 
metandienone, and nandrolone) 
or methanol (stanozolol) solution 
Final concentration of 
organic solvent 
0.5% 1% 
MgCl2 concentration 5 mM 5 mM 
Initiation 5 μL of 20 mM NADPH 5 μL of 20 mM NADPH 
Cosubstrate addition - 5 μL of 20 mM NADPH at 6, 12, 
and 18 h 
Incubation time 2 h 1, 3, 6, 12, 18, and 24 h 
Termination by protein 
precipitation 
200 μL ice-cold acetonitrile, and 
transfer of the tubes to -18 ?C 
for 30 min 
10 μL 4 M perchloric acid, and 
transfer of the tubes into an ice 
bath 
Removal of 
precipitated HLMs 
centrifugation at 13200 rpm for 
10 min 
centrifugation at 13200 rpm for 
10 min 
Pooling - supernatants from 1, 3, 6, 12, 18, 
and 24 h incubations 
Pretreatment - Solid-phase extraction (see 
Section 3.2.5) 
3.2.3 Electrochemical oxidation 
The test solution contained 10 μM buspirone, promazine, testosterone, or 7-ethoxycoumarin 
in acetonitrile:water 50:50 + 0.1% formic acid (EC-acidic). In the case of testosterone and 
7-ethoxycoumarin, no products were observed at 10 μM concentration and the concentration 
was increased to 100 μM. Also basic conditions (EC-basic) were tested for the oxidation of 
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buspirone and promazine, with acetonitrile:water 50:50 + 0.1% ammonium hydroxide used 
as the solvent. The solution was infused at a flow rate of 50 μL min-1 through the 
electrochemical ESA 5021A conditioning cell with a working electrode of porous graphite 
(ESA Inc., Bedford, MA, USA). The electrochemical cell was controlled by an ESA 
Coulochem III potentiostat (ESA Inc.). All reported cell potentials are versus a palladium 
reference electrode. The potential was ramped from 0 to 1500 mV with steps of 10 mV / 3.6 
s. All the potential ramp experiments were made in duplicate. Online-ESI-MS was used to 
monitor the formed products. Samples for UHPLC-MS analysis were collected at constant 
potentials chosen on the basis of the potential ramp experiments (Table 7). The samples 
were diluted 10-fold with water before UHPLC-MS analysis. 
 
 Constant potentials used for sample collection in direct EC. 
Compound EC-acidic, potential (mV) EC-basic, potential (mV) 
Buspirone 800, 1000, 1200, 1500 800, 1000, 1200, 1500 
Promazine 500, 600, 1000, 1200, 1500 600, 700, 800, 1000 
Testosterone and  
7-Ethoxycoumarin 
No products observed in ramps in acidic conditions ? no sample 
collected with constant potentials 
3.2.4 Electrochemically assisted Fenton reaction 
The EC-Fenton setup used for buspirone, promazine, testosterone, and 7-ethoxycoumarin 
(II) was based on the methods previously reported.[26, 51] Each reaction mixture (550 μL) 
consisted of 50 μL 10 mM substrate (in water or acetonitrile), 50 μL 10 mM EDTA/FeCl3 
in water, 125 μL or 75 μL acetonitrile, 275 μL or 325 μL water (depending on whether the 
sample was in water or acetonitrile, respectively) and 50 μL 0.1 M hydrogen peroxide 
(added just before the start of infusion through the EC cell). An ESA 5021A conditioning 
cell with a working electrode of porous graphite was used for EC-Fenton reactions. Samples 
were infused through the electrochemical cell first at a flow rate of 50 μL min-1. After 1 
min, the flow rate was lowered to 2 μL min-1 and a potential of -500 mV was applied. Sample 
collection was started after 15 min. The samples were diluted 25-fold with water before 
UHPLC-MS analysis. 
3.2.5 Solid-phase extraction 
For the anabolic steroids (III), the second supernatant (450 μL) of photocatalytic reactions 
and the pooled supernatant (270 μL) from HLM incubations, used for comparison of the 
reaction products, were diluted each with 1 mL of 100 mM ammonium acetate buffer (pH 
6.0) for solid-phase extraction. Waters Oasis 30 mg 1 mL cartridges were conditioned with 
1 mL of methanol and 1 mL of purified water. The sample was loaded to the cartridge, 
which was then washed with 1 mL of water-methanol 95:5 (v:v) and 1 mL of water-
methanol 95:5 (v:v) + 2% acetic acid. The steroids and reaction products were eluted from 
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the cartridge with 1.5 mL of acetonitrile (testosterone, methyltestosterone, metandienone, 
and nandrolone) or 1.5 mL of methanol (stanozolol). The samples were evaporated to 
dryness in a water bath under nitrogen. Dry residues were reconstituted in 100 μL (HLM 
samples) or 50 μL (photocatalysis samples) of the LC mobile phase A:B 75:25 (v:v) (Table 
8). 
3.3 Analytical methods and instrumentation 
3.3.1 Liquid chromatography – mass spectrometry 
ACQUITY UPLC™ (Waters, Milford, MA, USA) and Xevo™ Q-TOF-MS (Waters, 
Manchester, UK) were used for analysis of the reaction products of (phospho)peptides (I), 
small drug molecules (II), and anabolic steroids (III) (Table 8). The chromatographic 
gradients were optimized for each model compound and details can be found in the original 
publications (I-III). MS and MS/MS spectra were collected in the positive ion mode using 
electrospray ionization (ESI). MS data were centroided and corrected during acquisition 
using as external reference (Lockspray) leucine enkephalin (concentration 2 ng μL-1, flow 
rate 20 μL min-1) at m/z 556.2771.  
Metabolynx XS V4.1 software (Waters, Milford, MA, USA) was used in the search for 
unexpected reaction products (II, III). If a reaction product with the same m/z and retention 
time (tR) as in HLM experiments was found also in TiO2 photocatalytic reactions, 
electrochemical oxidation, or Fenton reaction, its product ion spectrum was compared with 
the product ion spectrum of the corresponding metabolite (see Table 8 for criteria).  
A TSQ Quantum AM (Thermo Fisher Scientific, Waltham, MA, USA) triple quadrupole 
mass spectrometer was used for online monitoring of products during EC potential ramps. 
The detailed parameters can be found in the original publication (II). 
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3.3.2 Desorption electrospray ionization – mass spectrometry integrated 
with titanium dioxide photocatalysis 
In DESI-MS, a home-built sprayer was used with Agilent Ion Trap 6330 (Agilent 
Technologies, Walbronn, Germany) in the positive ion mode (Figure 2). The ESI capillary 
(i.d. 83 μm, o.d. 184 μm) was grounded and the MS inlet capillary voltage was 2000 V. 
Nebulizer gas (N2) was introduced at 9.5 bar through the outer capillary (i.d. 0.25 mm). The 
sprayer was attached to an x-, y-, z-stage, aligned parallel to the MS inlet, on-axis, with the 
following geometry: impact angle ?60°, vertical distance from sprayer to sampling surface 
?4 mm. The sampling surface was level with the lower edge of flared capillary extension 
inlet (i.d. 1.6 mm). The horizontal distance of the sample to the MS inlet was ?10 mm. 
Methanol/water (1:1, v:v) + 0.1% formic acid was used as the spray solvent at the flow rate 
of 3 μL min−1. The TiO2-coated glass wafer used as a sampling surface was placed on a 
rotating platform (Thorlabs CR1-Z7/M, Thorlabs Sweden AB, Gothenburg, Sweden), 
which was placed on an x-, y-, z-stage. The rotation of the platform was controlled by 
Thorlabs computer software APT motor controller. 
 
 
Figure 2 TiO2 photocatalysis–DESI-MS rotating array platform setup. 
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4 Results and discussion 
4.1 Photocatalytic oxidation of phosphopeptides 
As phosphorylation of the tyrosine residue has a key role in the cellular processes, its effect 
on the oxidation process mediated by ROS was addressed in this study (I). A TiO2 
photocatalytic oxidation method was developed to compare the effect of phosphorylation 
with the help of five peptides, which had the same sequence (TRDIYETDYYRK), and three 
tyrosine (Y) residues of which none (IR0), all (IR3), or one was phosphorylated (IR1A, 
IR1B, and IR1C). UHPLC-ESI-MS methods were developed for the analysis of reaction 
products. 
4.1.1 Optimization of duration of exposure to ultraviolet radiation 
First, the duration of the UV exposure for the TiO2 photocatalytic oxidation of the studied 
(phospho)peptides was optimized. The peptides decomposed under TiO2 photocatalysis 
within 15 min (Figure 3). The initial, but not always the most abundant, oxidation products 
were M+O and M+2O products, on which this study concentrated. All initial oxidation 
products of each peptide formed and degraded following similar kinetics. The UV exposure 
time yielding the greatest abundance of M+O and M+2O products was chosen for the 
structural elucidation of the M+O and M+2O products (Figure 3), and was 2 min for IR1A 
and IR1C, 4 min for IR0, and 6 min for IR1B. The UV exposure time was not optimized for 
IR3, as no oxidation products were observed with UV exposure time of either 1 min or 6 
min. 
 
 
Figure 3 Degradation of peptides IR0, IR1A, IR1B, and IR1C and formation of initial reaction 
products under TiO2 photocatalysis (calculated using the triply protonated ion). 
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4.1.2 Identification of photocatalytic oxidation products of 
(phospho)peptides 
The mass spectra of peptides IR0, IR1A, IR1B, IR1C, and IR3 analyzed by the developed 
UHPLC-ESI-MS method showed multiple protonated molecules (one to four protons). The 
triple protonated molecule [M+3H]+3 was the most abundant ion for nearly all peptides and 
their M+O and M+2O oxidation products. Thus, it was selected as the precursor ion for 
product ion analyses. The most common product ions of the peptides were sequence 
diagnostic single protonated N-terminal b-ions and C-terminal y-ions. The oxidation sites 
of the M+O and M+2O products of the studied peptides were determined based on the 
oxidized and the nonoxidized b- and y-ions of the peptides (Table 9). As an example, the 
product ion spectrum of the M+O product of IR0 eluting at 1.90 min showed an oxidized 
y4-ion and a nonoxidized y3-ion, indicating that the oxidation site was Y9.  Similar data 
interpretation also applies to the other identifications.  
TiO2 photocatalysis produced five M+O products of IR0, eight M+O and five M+2O 
products of IR1A, two M+O products of IR1B, and five M+O products of IR1C (Table 9). 
Traces of M+2O products of IR0, IR1B, and IR1C were also observed, but at quantities 
lower than those needed for reliable identification based on acquisition of the product ion 
spectra. By considering all oxidation products, the oxidation site was at a 
nonphosphorylated tyrosine (Y) in 21 products, at a phosphorylated tyrosine in two 
products, and at isoleucine 4 (I4) in two products. Thus, the nonphosphorylated peptide IR0 
and the monophosphorylated peptides IR1A, IR1B, and IR1C were preferentially oxidized 
at nonphosphorylated tyrosines. This is in agreement with the reaction rate constant of 
tyrosine with hydroxyl radicals, which is at least an order of magnitude higher than that of 
the other amino acids present in the studied peptides.[22] The two observed M+2O products 
of isoleucine (based on diagnostic b4+2O ion) are consistent with the reaction rate constant 
of hydroxyl radicals with isoleucine (1.8×109 M-1s-1), being the third highest after tyrosine 
and arginine, and approximately an order of magnitude higher than those of the other amino 
acids (7.5×107–5.1×108 M-1s-1) present in the studied IR peptides.[22] Interestingly, both 
oxygens in the M+2O oxidation products attacked the same amino acid.  
Although the favored oxidization site was shown to be at a nonphosphorylated tyrosine, 
IR1A and IR1C each produced a minor M+O product, in which the oxidation site was the 
phosphorylated tyrosine. However, no oxidation products of the triply phosphorylated 
peptide IR3 (all tyrosines phosphorylated: pY5, pY9, and pY10) were observed. Thus, the 
results suggest that phosphorylation of tyrosine significantly inhibits its oxidation under 
TiO2 photocatalysis conditions. 
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 Proposed diagnostic product ions of the reaction products. Accurate masses of the 
precursors and product ions can be found in the Supporting Information of original 
publication I.  
Nonoxidized product ions are marked 
with X, singly oxidized product ions 
(X+O) are marked with O, and doubly 
oxidized product ions (X+2O) are 
marked with 2O. 
Pept./ 
prod. 
Oxidation 
site 
tR 
(min) 
Prec. 
[M+3H]3+ 
b4 b5 b6 y3 y4 y5 y6 Otherc 
IR0 - 5.98 541.6 X X X X X X X  
M+O Y9 1.90 546.9 X X X X O O O  
M+O Y10* 2.42 546.9 X X X O O O O  
M+O Y5 4.31 546.9 X O O X X X X  
M+O Y9 & Y10a* 4.57 546.9 X X X X/O O O O  
  
          
 
IR1A - 5.43 568.3 X X X X X X X  
M+O Y9 2.09 573.6 X X X X O O O  
M+O Y9 & Y10a* 2.29 573.6 X X X X/O O O O   
M+O Y9 & Y10a* 2.57 573.6 X X X X/O O 
 
O   
M+O Y9 & Y10a* 4.00 573.6 X X X X/O O O O   
M+O pY5 7.00 573.6 X O O X X X X  
M+2O Y9 2.62 578.9 X X X X 2O 2O 2O  
M+2O I4 2.94 578.9 2O 2O 2O X X X X b3 
M+2O Y10 3.13 578.9 X X 
 
2O 2O 2O 
 
x2 
M+2O Y9b 3.30 578.9 X X X 
    
b8, z3 
M+2O I4 3.67 578.9 2O 
  
X X X X b3 
  
          
 
IR1B - 9.64 568.3 X X X X X X X  
M+O Y5 7.42 573.6 X O O X X X X  
M+O Y10* 7.57 573.6 X X X O 
 
O O  
   
IR1C - 5.20 568.3 X X X X X X X  
M+O Y9 1.94 573.6 X X X X O O O  
M+O Y9 2.14 573.6 X X X X O O O  
M+O Y5 3.61 573.6 X O O X X X X  
M+O Y9 3.80 573.6 X X X X O O O  
M+O pY10* 8.29 573.6 X X X O O O O  
aTwo oxidation products that could not be resolved chromatographically. 
 bNo oxidized product ions were observed, but the nonoxidized product ions rule out there being other 
oxidation sites.  
cOther diagnostic product ions (nonoxidized). 
*y1- and y2-ions were not observed in the product ion spectra, and hence, the assignment of the oxidation site 
is not explicit. Y10 was assumed to be more readily oxidized than arginine 11 (R11) or lysine 12 (K12), as the 
reaction rate of hydroxyl radicals with Y (1.3×1010 M-1s-1) is approximately an order of magnitude higher than 
with R (3.5×109 M-1s-1) and two orders of magnitude higher than with K (3.5×108 M-1s-1).[22] 
Pept. peptide, prod. product, Prec. precursor ion  
 37 
 
The two products in which the oxidation site was a phosphorylated tyrosine eluted later 
in the reversed-phase C18 liquid chromatography conditions than did the respective 
nonoxidized peptide (Table 9). Instead, the M+O and M+2O products in which the oxidation 
occurred at a nonphosphorylated tyrosine eluted earlier than the respective nonoxidized 
peptides. Thus, oxidation of the phosphorylated tyrosine rendered the peptide more 
hydrophobic, increasing its retention within the C18 column, whereas oxidation at a 
nonphosphorylated tyrosine yielded more polar products, with decreased retention relative 
to the respective nonoxidized peptide. Hydroxylation of a phosphorylated tyrosine may 
enable internal hydrogen bonding between the formed hydroxyl group and the phosphate 
group, thus rendering the peptide more hydrophobic (Figure 4).  
 
 
Figure 4 Internal hydrogen bonding may cause the increased hydrophobicity of the peptide 
oxidized at the phosphorylated tyrosine. 
4.1.3 Mechanism of photocatalytic oxidation of (phospho)peptides 
The possible oxidant species involved in TiO2 photocatalysis include the hole on the 
TiO2 surface, the hydroxyl radical, the superoxide ion, and the singlet oxygen.[99] In 
addition, hydrogen peroxide and molecular oxygen are involved in the photocatalytic 
oxidation reactions. The reaction rate of hydroxyl radical with tyrosine (1.3×1010 M-1s-1)[22] 
is significantly higher than those of either the superoxide ion or the singlet oxygen 
(1.0±0.2×101 M-1s-1 and 0.8–0.9×107 M-1s-1, respectively).[10] Moreover, the oxidation of 
tyrosine residue is more likely to be mediated by hydroxyl radicals than by surface holes 
since basic reaction conditions (pH 10.5) were chosen to prevent the adsorption of the 
peptides onto the TiO2 surface. At this pH, the TiO2 surface is negatively charged[105] and 
electrostatic repulsion orients the negatively charged phenolic moiety of the tyrosine residue 
and the negatively charged phosphate group at the phosphorylated tyrosine out from the 
TiO2 surface, which results in decreased interaction and oxidation of tyrosine residues of 
the peptides with the holes. It has also been suggested that organic molecules should be 
adsorbed onto the TiO2 surface[103] to react with the short-lived singlet oxygen (lifetime 2-
3 μs).[102] Hence, hydroxyl radicals obviously play a major role in initiating oxidation 
reactions of the tyrosine residue of the studied peptides.  
Xu and Chance presented a scheme for a hydroxyl radical-initiated oxidation mechanism 
of tyrosine residue[22] in which the hydroxyl radical reacts rapidly with the tyrosine residue 
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that produces the dihydroxycyclohexadienyl radical (Figure 5). The most obvious reaction 
site is the meta-position, due to the directing effect of the original hydroxyl substituent at 
the para-position. The dihydroxycyclohexadienyl radical then reacts with oxygen (via 
addition), followed by the elimination of the hydroperoxyl radical to form α-
hydroxycyclohexadienone, which is finally converted to 3,4-dihydroxyphenylalanine 
residue (DOPA) (M+O product). Further hydroxylation of DOPA via the same oxidation 
mechanism can produce trihydroxyphenylalanine residue (M+2O product). The inhibitory 
effect of phosphorylation upon the oxidation of tyrosine may be explained by the presented 
oxidation mechanism. The phosphorylation of the hydroxyl group of tyrosine (para-
position) prevents the formation of the α-hydroxycyclohexadienone intermediate, and thus, 
inhibits oxidation of phosphorylated tyrosine. Even if the two meta-positions of each 
tyrosine are the favored oxidation sites, our results suggest that oxidation may also occur at 
other positions since four different M+O products of IR1A were oxidized at Y9, three 
different M+O products of IR1A were oxidized at Y10, and three different M+O products 
of IR1C were oxidized at Y9. However, the exact oxidation site at tyrosine was not 
elucidated in this study. 
 
 
Figure 5 Hydroxyl radical-mediated oxidation of tyrosine (adapted from [22]).  
4.2 Imitation of phase I metabolism by titanium dioxide 
photocatalysis  
First, the TiO2 photocatalytic reaction conditions were optimized for oxidation of small drug 
molecules with different polarities using buspirone and testosterone as model compounds 
(II, III). The feasibility of TiO2 photocatalysis for imitation of phase I metabolism was 
compared with that of EC-Fenton and direct EC (II). Buspirone, promazine, testosterone, 
and 7-ethoxycoumarin were chosen as test compounds as their metabolism covers the most 
common phase I reactions such as aliphatic hydroxylation, aromatic hydroxylation, N-
oxidation, S-oxidation, N-dealkylation, and O-dealkylation. The reaction products from 
TiO2 photocatalysis, EC-Fenton, and direct EC reactions were compared with the phase I 
metabolites produced in vitro by human liver microsomes. The feasibility of TiO2 
photocatalysis for imitation of phase I metabolism of anabolic steroids was studied by 
comparing the photocatalytic reaction products of metandienone, methyltestosterone, 
nandrolone, stanozolol, and testosterone to the in vitro phase I HLM metabolites (III). 
UHPLC-ESI-MS methods were developed for the analysis of reaction products (II, III). 
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4.2.1 Optimization of photocatalytic reaction conditions 
In TiO2 photocatalysis, addition of organic solvent to water was necessary in order to 
increase the solubility of anabolic steroids and 7-ethoxycoumarin. Acetonitrile was selected 
as an organic solvent because it has weaker radical scavenging activity than methanol[135] 
The effect of acetonitrile on the photocatalytic oxidation reaction rates and routes was 
studied using three different solvent conditions per compound: 100% water, 1% and 50% 
acetonitrile in water were used for buspirone (II), whereas 1%, 50%, and 95% acetonitrile 
in water were used for testosterone (III). 
The reaction products formed very fast in 100% water, and the intensity of the main 
products of buspirone was highest at 15 s (Figure 6). At longer UV exposure times, the 
initial products underwent further reaction or degradation. Acetonitrile effectively slowed 
down the photocatalytic reactions even at 1% concentration, and the highest intensity of the 
main products was observed at 2 min. The effect was even more pronounced at 50% and 
95% concentrations of acetonitrile. At 50% acetonitrile concentration, the intensities of the 
products continuously increased within the 30-min time-frame studied. In 95% acetonitrile, 
however, the formation of the products became slower than their degradation by the end of 
the 30-min period. 
Acetonitrile scavenges hydroxyl radicals,[135] which slows down the hydroxyl radical-
mediated photocatalytic reaction. Acetonitrile was found not only to inhibit but also to direct 
the photocatalytic reactions; the increase of acetonitrile concentration completely inhibited 
a few of the products formed at the lowest acetonitrile concentration (buspirone 0%, 
testosterone 1%) (Figure 7). In addition, completely new products not observed at the lowest 
acetonitrile concentration were formed with increasing acetonitrile concentration (Figure 
7). Detailed lists of the reaction products can be found in original publications II (buspirone) 
and III (testosterone). The reaction products of buspirone in 100% water and testosterone in 
1% acetonitrile were similar to those described in Sections 4.2.2 and 4.2.3, even though not 
all the isomeric compounds were separated in the reaction condition optimization phase.  
The increase of acetonitrile concentration also changed the relative abundances of the 
reaction products. As an example, 100% water favored formation of a 
hydroxylation+dehydrogenation product (M+O-2H, m/z 400, tR 4.51 min) of buspirone over 
the formation of dehydrogenation (M-2H, m/z 384, tR 5.47 min) and N-,N-deethylenation 
(M-C2H2 m/z 360, tR 4.45 min) products (Figure 6). Increasing acetonitrile concentration 
clearly inhibited formation of the M+O-2H product and favored formation of the M-2H and 
M-C2H2 products of buspirone. In the case of testosterone, the same products were observed 
in 1% and 50% acetonitrile (Figure 7), although their relative intensities were different. 
Acetonitrile concentrations of 50% and 95% clearly favored the formation of a 
dehydrogenation product (M-2H, m/z 287.20, tR 3.34 min) over the formation of 
hydroxylation (M+O, m/z 305.21, tR 2.99 min) and hydroxylation+dehydrogenation (M+O-
2H, m/z 303.19, tR 2.67 min) products, whereas these three product types were formed with 
relatively similar abundances in 1% acetonitrile (Figure 6). In general, the formation of 
M+O and M+O-2H products was less abundant and slower in 95% acetonitrile than in 50% 
acetonitrile. The addition of acetonitrile, having electron scavenging capability, inhibited 
formation of ROS, and thus, formation of hydroxylation products. Therefore, at higher 
acetonitrile concentrations buspirone and testosterone instead reacted directly with the 
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photogenerated holes on the TiO2 surface via one electron oxidation to produce 
dehydrogenation and, in the case of buspirone, N-dealkylation products. 
 
 
Figure 6 Degradation of buspirone and testosterone and formation of selected reaction 
products in TiO2 photocatalysis. 
Higher acetonitrile percentages with longer UV exposure times produced greater 
abundance of oxidation products in most cases (Figure 6). This is probably due to the slower 
degradation of formed products and may be useful in photocatalytic synthesis of metabolite 
standards. The possibility to use acetonitrile as a solvent enables oxidation of very poorly 
water-soluble compounds by TiO2 photocatalysis. However, the amount of acetonitrile was 
kept to a minimum in this study in order to simulate physiological conditions and because 
the reactions were much faster and more convenient than with higher acetonitrile 
percentage. Thus, UV exposure times of 15 s and 2 min were chosen for TiO2 photocatalysis 
in 100% water (buspirone and promazine) and 1% acetonitrile (metandienone, 
methyltestosterone, nandrolone, testosterone, and 7-ethoxycoumarin), respectively. 
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Stanozolol was not soluble enough in 1% acetonitrile, and thus, 50% acetonitrile and UV 
exposure time of 15 min were chosen for stanozolol.   
 
 
Figure 7 Effect of acetonitrile on the TiO2 photocatalytic reaction products of buspirone and 
testosterone. 
4.2.2 Comparison of titanium dioxide photocatalysis, electrochemical 
oxidation, and electrochemically assisted Fenton reaction for imitation of 
phase I metabolism  
The TiO2 photocatalytic, EC, and EC-Fenton reaction products of buspirone, promazine, 
testosterone, and 7-ethoxycoumarin were compared with the in vitro phase I HLM 
metabolites using UHPLC-MS (II). The high resolving power of the UHPLC allowed 
separation of nearly all isomeric compounds. The good repeatability of the retention times 
(RSD typically less than 0.5%), together with the mass spectrometric data, enabled reliable 
comparison of the products of different oxidation methods. All reaction products were 
observed as protonated molecules. In most cases, the product ion spectra of the imitation 
reaction products and HLM metabolites with the same m/z of the protonated molecule 
(tolerance 30 ppm) and retention time (tolerance 0.05 min) correlated well, indicating that 
products and metabolites identified on the basis of m/z and retention time were indeed the 
same. In the few cases where the product ion spectra were different, products having the 
same retention time and precursor ion probably were different isomers. 
To compare the reaction product profiles of different oxidation methods, the abundances 
of the reaction products were normalized relative to the most abundant reaction product 
obtained with the particular method. Products were classified as major (S), medium (M), or 
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minor (W) according to their relative abundances (50–100%, 20–50% and 5–20%, 
respectively). In view of the many trace products, reaction products of less than 5% relative 
abundance were excluded from the comparison of the reaction products. Figure 8 shows the 
main reaction pathways of buspirone, promazine, testosterone, and 7-ethoxycoumarin. The 
product ion spectra allowed tentative structural assignment of most reaction products of 
buspirone, promazine, and 7-ethoxycoumarin. The oxidation sites of the isomeric reaction 
products of testosterone could not be identified based on the product ion spectra, but a major 
product was identified as androstenedione using a standard. The detailed comparison of the 
reaction products formed in HLM incubations, TiO2 photocatalysis, EC-Fenton, and direct 
EC is presented in Tables 10-13, and the reactions are briefly discussed by compound. 
 
Buspirone 
The HLM metabolism reactions of buspirone included aromatic hydroxylation, aliphatic 
hydroxylation of R3 and R4 with or without subsequent dehydrogenation, N-oxidation of 
R2, loss of the ethylene group from R2, N-dealkylation between R2 and R3, and 
combinations of these (Table 10, see Figure 8 for explanation of the R-groups). All of these 
reaction types, except N-oxidation, were observed in TiO2 photocatalysis and EC-Fenton, 
but the combinations of reactions and isomers were often different from those in HLM 
metabolism. The oxidation reactions were mostly similar in TiO2 photocatalysis and EC-
Fenton, and typically proceeded further than in HLMs; for example, dehydrogenation 
followed hydroxylation, and multiple hydroxylations of pyrimidine and opening or 
fragmentation of the pyrimidine ring were observed. EC was not capable of aromatic or 
aliphatic hydroxylation, but was the only imitation method that produced N-oxides, as 
suggested by the late elution[117] and the product ion spectra of these products.  
 
Promazine 
HLM metabolism reactions of promazine included N-demethylation, S-oxidation, aromatic 
hydroxylation, N-oxidation, and dehydrogenation, alone or in different combinations (Table 
11, Figure 8). TiO2 photocatalysis and EC-Fenton mainly produced sulfoxides and aromatic 
hydroxylation products. EC also produced sulfoxides and was the only imitation method 
capable of N-dealkylation of promazine. None of the imitation methods produced the HLM 
metabolite promazine N-oxide. Again, the oxidation typically proceeded further in TiO2 
photocatalysis and EC-Fenton than in HLM reactions. 
 
Testosterone 
The main reactions of testosterone in phase I HLM metabolism, TiO2 photocatalysis, and 
EC-Fenton reactions were hydroxylation and dehydrogenation and combinations of these, 
but the isomers were partly different in each system (Table 12, Figure 8). Minor reactions 
unique to each of the systems were also observed. Direct EC failed to oxidize testosterone 
at all.  
 
7-ethoxycoumarin 
TiO2 photocatalysis and EC-Fenton imitated only the main HLM metabolism reaction of 7-
ethoxycoumarin, which was O-deethylation leading to 7-hydroxycoumarin (Table 13, 
Figure 8). Overall, the HLM, TiO2 photocatalysis, and EC-Fenton reactions of 7-
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ethoxycoumarin produced only a few products. Direct EC failed to oxidize 7-
ethoxycoumarin at all.  
 
 
Figure 8 Pathways for formation of the main reaction products of buspirone, promazine, 
testosterone, and 7-ethoxycoumarin in HLM metabolism, TiO2 photocatalysis, EC-Fenton, 
and direct EC (see Table 1 for examples of the reactions).  a Aromatic hydroxylation of the 
3-position most likely [136]; b Allylic hydroxylation of the 6β-position most likely. [137, 138] 
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 Imitation of HLM metabolites of testosterone by TiO2 photocatalysis, EC-Fenton, 
and EC.  
[M+H]+ (calc.) Reaction product Formula tR (min) HLM TiO2 EC-Fenton 
289.217 Testosterone C19H28O2 9.44 x x x 
305.212 M+O a, b C19H28O3      
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
3.41 
  
W 
4.25 M W W 
4.54 
 
W W 
4.82 
  
W 
5.35 S 
 
W 
5.87 M W M 
6.34 
 
W W 
6.72 W W* W* 
6.94 W 
  
6.99 
 
W W 
7.20 W W W 
7.50 M 
  
287.201 M-2H a, c 
  
  
C19H26O2 
  
  
    
8.72 S S S 
9.13 
 
W M* 
9.25 W W M* 
303.196 M+O-2H  C19H26O3 
    
   4.14 W   
     4.55 
 
M W 
     4.97 
 
W 
 
     5.12 W 
  
     5.32 
  
W 
     5.40 W M W 
     6.01 
 
W W 
     6.42 
 
W W 
     7.29 W 
  
285.186 M-4H C19H24O2 8.26 W 
  
301.180 M+O-4H C19H24O3 2.37 W 
323.186 M+3O-CH2 C18H26O5 9.96 
  
M 
S = 50–100%, M = 20–50%, W = 5–20% of the peak area of the most abundant reaction product of the 
particular method. 
a Observed earlier in HLM incubations: androstenedione, 1α-, 1β-, 2α-, 2β-, 6α-, 6β-, 7α-, 11β-, 15β-, 16α-, 
16β-, and 18/12α-hydroxylation, 6β the major hydroxylation site (see Figure 8) [137, 138, 143, 144];  
b Observed earlier in EC-Fenton experiments: two M+O products [26];  
c The major M-2H product was androstenedione, as confirmed through comparison with a standard by MS/MS. 
* The product ion spectrum does not correlate well enough with the spectrum of the HLM metabolite, 
indicating different isomers. 
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 Imitation of HLM metabolites of 7-ethoxycoumarin by TiO2 photocatalysis, EC-
Fenton, and EC.  
[M+H]+ 
(calc.) 
Reaction 
product 
Formula tR 
(min) 
Tentative 
structural 
assignment 
HLM TiO2 EC-
Fenton 
191.071 7-ethoxy-
coumarin 
C11H10O3 6.64  x x x 
163.040 M-C2H4 a C9H6O3 3.79 Deethylation to 
7-hydroxycoumarin 
S M S 
183.102 M+O+4H-CO C10H14O3 4.64  M 
  
179.034 M+O-C2H4 C9H6O4 2.73 Hydroxylated 7-
hydroxycoumarin b 
W 
  
197.081 M+O-CH2+4H C10H12O4 3.92  W 
  
205.050 M+O-2H C11H8O4 4.32 Hydroxylation and 
dehydrogenation of 
the ethylene moiety 
 
S S 
207.066 M+O a C11H10O4   
   
   4.69 Hydroxylation of 
coumarin 
  M 
 
 
 4.78 
 
M W 
S = 50–100%, M = 20–50%, W = 5–20% of the peak area of the most abundant reaction product of the 
particular method.  
a Observed earlier in HLM incubations: 7-hydroxycoumarin, 3- and 6-hydroxylations [143]; b 3-hydroxylation 
(see Figure 8 for numbering) is most likely to occur.[145, 146] 
 
TiO2 photocatalysis was able to produce almost half (44%) of the HLM metabolites; the 
coverage was considerably poorer for EC-Fenton (31%), and direct EC (coverage 11%) 
failed to produce most of the HLM metabolites (Equation 2). All of the imitation methods 
produced also several products other than HLM metabolites (Figure 9). In total, EC 
produced the smallest number of reaction products, whereas TiO2 photocatalysis, EC-
Fenton, and HLM reactions were close to each other in the total number of reaction products. 
The main phase I HLM metabolism reactions of the model drugs covered the most 
common phase I reactions such as hydroxylation, dehydrogenation, N-dealkylation, O-
dealkylation, N-oxidation, and S-oxidation (Table 14). All of these reaction types, except 
N-oxidation, were observed commonly in TiO2 photocatalysis and EC-Fenton reactions, 
where the hydroxyl radical-based mechanism enables reactions beginning with hydrogen 
atom abstraction. However, TiO2 photocatalysis and EC-Fenton reaction often overoxidized 
the compounds (e.g. hydroxylation followed by dehydrogenation) as compared with in vitro 
metabolism. Direct EC was mainly capable of N-dealkylation and S-oxidation reactions, 
which can begin with single electron transfer. TiO2 photocatalytic reaction can begin both 
by hydrogen atom abstraction by hydroxyl radicals and by single electron transfer to an 
electron hole on the TiO2 surface, both of which are essential mechanisms in CYP450 
catalyzed phase I metabolism. This may account for the better ability of TiO2 photocatalysis 
to imitate HLM metabolites relative to EC and EC-Fenton. TiO2 photocatalysis was also 
much faster than EC-Fenton and the traditional in vitro methods.  Despite the possibility for 
the same reaction types, different isomeric products and combinations of reactions often 
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occurred, owing to the different selectivities of the compared oxidation methods. All in all, 
the highly selective enzymatic reactions cannot be comprehensively imitated by any of the 
imitation methods and none of the compared imitation methods allow exact prediction of 
the metabolism of a novel drug. Nonetheless, some of the imitation reaction products not 
found in HLM could be clinically relevant, as all of the drug-metabolizing enzymes are not 
present in HLMs. In addition, other nonbiological oxidation products could form through, 
for example, incorrect storage of the medicinal preparation.  
 
(2) ???????? ?
??????????????????????????????????????
???????????????????????????? ????????????
???????????????? ??????????????????????? ?? ??????? 
 
 
Figure 9  Summary of imitation of HLM metabolites of buspirone, promazine, testosterone, and 
7-ethoxycoumarin by TiO2 photocatalysis, EC-Fenton, and EC. The number of the products 
is given in the bars. No reaction products of testosterone and 7-ethoxycoumarin were 
observed in EC-acidic. 
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4.2.3 Imitation of phase I metabolism of anabolic steroids by titanium 
dioxide photocatalysis 
Compared with EC and EC-Fenton, TiO2 photocatalysis proved the most suitable for 
oxidation of nonpolar compounds such as testosterone (II). Thus, TiO2 photocatalysis was 
also applied to imitation of phase I metabolism of anabolic steroids (III). The photocatalytic 
reaction products of commonly used doping substances metandienone, methyltestosterone, 
nandrolone, stanozolol, and testosterone were compared with their phase I metabolites 
produced by HLMs.  
The good chromatographic performance of the developed UHPLC-MS method was 
recognized as narrow, and non-tailing peaks, and relative standard deviations of retention 
times were typically less than 0.25%. This allowed separation of several isomeric oxidation 
products formed in HLM metabolism and TiO2 photocatalysis. ESI mass spectra of the 
anabolic steroids and their oxidation products showed an abundant protonated molecule 
with few fragment ions typically formed by the loss of one or two water molecules. A few 
products observed with the same m/z and retention time in the HLM metabolism and TiO2 
photocatalysis showed, however, differing product ion spectra, indicating that these 
products were different isomers. The different isomeric products can be attributed to the 
different selectivity of the enzymatic reactions and the hydroxyl radical attack in TiO2 
photocatalysis. 
The main reaction types both in TiO2 photocatalysis and phase I HLM metabolism of 
the anabolic steroids were hydroxylation (M+O), dehydrogenation (M-2H), and a 
combination of these (M+O-2H) (Figure 10, see Table 1 for examples of the reactions). In 
total, TiO2 photocatalysis produced 31% of all the HLM reaction products of all the steroids 
studied (Equation 2). The HLM metabolites and photocatalytic reaction products of 
testosterone conformed well to those found in Study II. As a whole, the main phase I HLM 
metabolism reactions of methyltestosterone, nandrolone, testosterone, and stanozolol were 
imitated considerably better than those of metandienone. The reaction products are briefly 
discussed by product type below. 
TiO2 photocatalysis produced 50% of the M-2H metabolites of the anabolic steroids 
studied (Equation 2). The M-2H metabolites of structurally similar methyltestosterone, 
nandrolone, and testosterone were imitated well by TiO2 photocatalysis (Figure 10). The 
main M-2H product of testosterone was identified as androstenedione by comparison of the 
product ion spectrum to that of a standard. 17-keto metabolites are the main excreted 
metabolites of anabolic steroids having a secondary 17β-hydroxy group such as testosterone 
and nandrolone (see testosterone in Figure 10 for numbering of the steroid skeleton).[147] 
Thus, the main M-2H product of nandrolone is most likely formed by oxidation of 17β-
hydroxyl to ketone. Metandienone, methyltestosterone, and stanozolol also formed an M-
2H metabolite each. Nevertheless, the 17α-methyl group of methyltestosterone, 
metandienone, and stanozolol should inhibit their 17β-oxidation. Therefore, the M-2H 
metabolite is likely to result from formation of a double bond in the steroid skeleton. The 
most obvious site of dehydrogenation in the steroid skeleton is the C6-C7 bond since in this 
case the increased degree of conjugation of double bonds stabilizes the product via π-
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electron delocalization. Dehydrogenation of the C6-C7 bond has also been observed in 
human in vivo metabolism of methyltestosterone[148] and metandienone.[147] A few isomeric 
M-2H products, which were not formed in HLM reactions, were formed in TiO2 
photocatalysis of each of the steroids. 
 
 
Figure 10 Imitation of steroid HLM metabolites by TiO2 photocatalysis.The number of the 
products is given in the bars. 
TiO2 photocatalysis imitated 55% the M+O metabolites of all the steroids studied 
(Equation 2). The M+O metabolites of metandienone were imitated remarkably poorer than 
those of other steroids (Figure 10). Seven hydroxylation products were observed in HLM 
metabolism of testosterone. These include most likely the 1β-, 2β-, 6β-, 11β-, 15β-, and 16β-
hydroxytestosterones previously found in HLM reactions, of which the 6β-hydroxylation 
product is the dominant metabolite.[137, 138, 144] Also minor 1α-, 2α-, 6α-, 7α-, 16α-, and 
18/12α-hydroxylation products of testosterone have been found in HLM incubations.[143] 
The metabolism of the other steroids used in this study has mainly been examined using 
human subjects,[149-151] various animal species,[152-154] or in vitro using liver preparations 
from different animals.[143, 155] These former studies cannot, however, be directly compared 
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with the HLM results in this work because of species differences in metabolism and 
differences between excreted metabolites and other metabolites formed in the body. 
Generally, TiO2 photocatalysis imitated the M+O-2H metabolites poorer (26%) than the 
M-2H and the M+O metabolites (Figure 10). The combination of two reactions can produce 
more possible isomers and the probability that the same isomers are formed in both systems 
is lower. In addition to M-2H, M+O, and M+O-2H products, dihydroxylation products 
(M+2O) were formed mainly in HLM reactions, and products formed by 
dihydroxylation+dehydrogenation (M+2O-2H) were favored by TiO2 photocatalytic 
reactions. This implies that the oxidation proceeds further in TiO2 photocatalysis than in 
HLM metabolism, as also observed in Study II. In addition, a few other minor oxidation 
products were observed in TiO2 photocatalysis (Figure 10). 
Importantly, TiO2 photocatalysis proved capable of producing over half of the M+O 
products of anabolic steroids. Capability of aliphatic hydroxylation is essential for the 
imitation of phase I metabolism of anabolic steroids, which can be enzymatically 
hydroxylated at numerous sites.[138, 141, 149, 150, 156, 157] TiO2 photocatalysis may provide a 
valuable way to oxidize also other nonpolar and hydrophobic compounds.  
4.3 Titanium dioxide photocatalysis – desorption electrospray 
ionization mass spectrometry rotating array platform 
TiO2 photocatalytic reactions are very fast, especially if no organic solvent is needed. 
However, the removal of the nanoparticles and the LC-MS analysis step are time-
consuming. A TiO2-coated nanoreactor μPESI chip provided much faster photocatalytic 
experiments than conventional methods.[31] The fabrication of μPESI chip is, however, 
demanding and requires the use of expensive clean-room facilities. To omit the complicated 
microfabrication and the need for pretreatment and to enhance the speed of analysis, a TiO2 
photocatalysis-DESI-MS rotating array platform for high-throughput screening of oxidation 
products was developed in this study. For this purpose, a round glass wafer was coated with 
photocatalytically active anatase-phase TiO2 using atomic layer deposition. The same TiO2-
coated glass wafer was used as a sample platform for photocatalytic reactions and DESI-
MS analysis (Figure 11). The performance of the TiO2 photocatalysis-DESI-MS rotating 
array platform was characterized and its capability for imitation of phase I metabolism 
reactions was studied using amodiaquine, buspirone, and verapamil as model drug 
compounds. The feasibility of the platform for high-throughput screening of oxidation 
products was investigated using 12 model drug compounds (amodiaquine, buspirone, 
verapamil, amphetamine, propranolol, metoprolol, nicotine, lidocaine, quinidine, 
moperone, atenolol, and nadolol). 
The X-ray diffraction analysis of the TiO2-coated glass wafer proved that the film crystal 
structure was photoactive polycrystalline anatase, which provides efficient and fast TiO2 
photocatalytic oxidation reactions.[31, 95-97] Microscopic examination of the coated wafer 
appearance and the UV-VIS reflectometry showed the TiO2 film was uniform, with a 
thickness of 100 nm ensuring repeatable oxidation experiments. Owing to the stability of 
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the film, the TiO2-coated glass wafer could be reused by washing the sample residues from 
the surface after DESI analysis.  
The volume of the sample needed for the oxidation reaction was only 1 μL. This is 
significantly less than in nanoparticle-based photocatalytic methods or in in vitro 
metabolism assays, where the sample volumes are typically hundreds of microliters. 
Approximately 70 samples could be introduced onto the rim of one TiO2-coated glass wafer 
(Figure 11), allowing high-throughput experiments.  
All samples on the TiO2-coated glass wafer could be exposed to UV at the same time 
offline using large diameter UV lamp (Figure 11a). UV exposure times of 30 s, 45 s, and 
120 s were the most suitable for producing oxidation products of verapamil, buspirone, and 
amodiaquine, respectively. Longer exposure times resulted in increased decomposition. 
Analysis of samples from an uncoated glass wafer with UV exposure as well as from TiO2-
coated glass without UV exposure showed no oxidation products. Thus, the oxidation 
products of the model compounds were formed only upon UV-initiated TiO2 photocatalytic 
oxidation reactions.  
Alternatively, the samples were UV exposed online while the TiO2-coated glass wafer 
rotated and transferred the exposed samples to DESI-MS analysis (Figure 11b). The reaction 
products of amodiaquine, buspirone, and verapamil obtained using online (100-120 s) UV 
exposure were similar to those obtained via offline exposure. In the online method, the 
exposure time was determined by the diameter of the UV beam and the rotation speed, 
which must be optimized to allow proper exposure and analysis times. Therefore, the offline 
mode offered higher throughput than the online mode in this work. 
 
 
Figure 11 A schematic picture of the experimental a) offline and b) online TiO2 
photocatalysis–DESI-MS rotating array platform setups (not in scale). MS = mass 
spectrometer. 
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The repeatability and sensitivity of DESI-MS analysis were dependent on the rotation 
speed of the wafer and positioning of the DESI sprayer and sample relative to the capillary 
extension inlet. In this work, the optimal rotation speed for maximum sensitivity and 
stability was 15 mm min-1, which allowed analysis of four samples within one minute. As 
previously reported,[158] the positioning of the DESI sprayer and the sample spot relative to 
the flared capillary extension inlet was not as critical as with a conventional “straight” 
capillary extension inlet. The signal-to-noise ratio was highest when the distance of the 
sample from the flared capillary extension inlet was between 10 mm and 17 mm and did not 
significantly change within this range. The repeatability of the method was tested with 
verapamil samples exposed to UV offline for 30 s (Figure 12). The average relative standard 
deviation of the peak areas of a six-replicate DESI-MS analysis of verapamil and its main 
oxidation products was 16%. The repeatability was typical for DESI-MS analysis,[159-161] 
although it also included the repeatability of TiO2 photocatalysis. 
 
 
Figure 12 Extracted ion profiles of verapamil (six parallel samples) and its main reaction 
products after offline TiO2 photocatalysis of 30 s. 
To demonstrate the feasibility of the TiO2 photocatalysis–DESI-MS rotating array 
platform for high-throughput screening of oxidation products, 12 drug compounds were UV 
exposed offline for 30 s. Oxidation products of all test compounds were observed using only 
one compromised UV exposure time (Table 15). However, optimization of the UV exposure 
time separately for each compound might enable more efficient conversion of the 
compounds to the products.  
The feasibility of the TiO2 photocatalysis–DESI-MS rotating array platform for 
imitation of drug metabolism reactions was studied with buspirone, verapamil, and 
amodiaquine as model drug compounds. The DESI-MS spectra of the model compounds 
and their oxidation products showed abundant protonated molecules ([M+H]+), which were 
used as precursor ions in MS/MS analysis. The main TiO2 photocatalytic oxidation products 
detected were formed by oxidation, hydroxylation, demethylation, and dehydrogenation and 
their various combinations (Table 16). The photocatalytic reaction products of buspirone 
and verapamil conformed well to the product types observed earlier in TiO2 photocatalysis 
and HLM metabolism (II).[30, 31] However, in the case of amodiaquine, only a minor 
hydroxylation product was observed. Aromatic hydroxylation of amodiaquine has been 
reported to occur in human in vivo metabolism[162, 163] as well as with recombinant 
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cytochrome P450 enzymes[164], but in combination with other reactions such as 
deethylation. Aromatic hydroxylation is catalyzed by CYP1A1 and CYP1B1 isoforms, 
which are mainly found in extrahepatic tissues, and therefore, the reaction is not observed 
in HLM incubations.[164] Nevertheless, the major metabolite of amodiaquine is 
deethylamodiaquine.[162, 163, 165] Detection of the reactive quinone imine metabolites of 
amodiaquine and deethylamodiaquine[166] would likely require conjugation with, for 
example, glutathione, imitating phase II metabolism. Imitation of phase II conjugative 
metabolism in combination with TiO2 photocatalysis was recently demonstrated by 
conjugating the reactive quinone imine formed in TiO2 photocatalytic oxidation of 
paracetamol.[46] Minor TiO2 photocatalytic oxidation of amodiaquine relative to verapamil 
and buspirone may relate to amodiaquine solution containing 0.25% acetonitrile (the stock 
solution was made in acetonitrile), as even 1% acetonitrile inhibited considerably the 
photocatalytic reaction performed with TiO2 particles (II). 
 
 TiO2 photocatalytic reaction products observed in high-throughput screening of 
oxidation products after 30 s offline UV exposure. 
 
 
Compound Reaction 
product 
[M+H]+  Compound Reaction 
product 
[M+H]+ 
Amodiaquine  356  Propranolol  260 
 M+O 372   M+2O 292 
Buspirone  386  Metoprolol  268 
 M+O 402   M+O-2H 282 
 M+O-2H 400  Nicotine  163 
 M+O-CH2 388   M+O 179 
 M-C2H2 360  Lidocaine  235 
 M+2O 418   M+O-2H 249 
 M+2O-2H 416   M+O 251 
 M-2H 384  Quinidine  325 
 M-16 370   M-2H 323 
 M-36 350   M+2O 357 
Verapamil  455   M+O 341 
 M-CH2 441  Moperone  356 
 M+O 471   M-HF 336 
 N-dealkylation 291   M+O 372 
 M+O-2H 469  Atenolol  267 
 M-2xCH2 427   M+O 283 
 M+2O 487  Nadolol  310 
Amphetamine  136   M-2H 308 
 M+O 152   M+O 326 
 M+O-2H 150   M+O-2H 324  
M+2O 168     
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 Reaction product types of buspirone, verapamil, and amodiaquine observed in 
TiO2 photocatalysis–DESI-MS experiments, HLM metabolism[31, 167] (II), and TiO2 
photocatalysis using nanoparticles (buspirone) or μPESI chip[31] (verapamil). 
 Reaction products 
observed in TiO2 
photocatalysis–DESI-MS 
[M+H]+ Observed 
earlier in HLM 
metabolism 
Observed earlier 
in TiO2 
photocatalysis 
Buspirone  386  Particle-based 
Main products M+O* 402 x x 
 M+O-2H* 400 x x 
 M+O-CH2 388  x 
Minor products M+2O 418 x x 
 M+2O-2H 416  x 
 M-C2H2 360 x x 
 M-2H 384 x x 
Verapamil  455  μPESI 
Main products M-CH2* (≥ 2 isomers) 441 x x 
 M-2xCH2* (≥ 2 isomers) 427 x  
 M+O  471 x x 
 M+O-2H* (≥ 3 isomers) 469 x x 
 M-164, N-dealkylation 291 x x 
Minor products M+2O 487 x  
 M+2O-CH2 473   
Amodiaquine  356 ** No data found 
 M+O* 372   
*Tentative structural assignment based on product ion spectra (Figure 13) 
** See the text above for the discussion of amodiaquine metabolism.  
 
Although DESI-MS does not allow separation of isomeric reaction products, the MS/MS 
analysis provides information of the modification site. The time-consuming LC-MS/MS 
analysis does not necessarily allow more precise determination of the modification site even 
if the reaction products are chromatographically separated. The product ion spectra of the 
main photocatalytic products in TiO2 photocatalysis-DESI-MS rotating array platform 
experiment allowed identification of oxidation sites of several reaction products (Figure 13). 
The interpretation of the product ion spectra can be found in Manuscript IV. In the case of 
buspirone, the oxidation sites of the reaction products could be identified using DESI-
MS/MS with similar precision as in LC-MS/MS analysis (II). However, the LC-MS/MS 
analysis allowed separation of several isomeric reaction products of buspirone, which were 
not observed based on the DESI-MS/MS spectra. In contrast, the DESI-MS/MS analysis of 
the M-CH2, M-2xCH2 and M+O-2H reaction products of verapamil allowed identification 
of several isomers. Nevertheless, TiO2 photocatalysis often produces different isomers than 
those produced by enzymes, and analysis of these isomers may require proper 
chromatographic separation to avoid false matches. Furthermore, the chromatographic 
separation of isomeric compounds provides a more exact number of the formed reaction 
products, facilitates the interpretation of the MS/MS spectra of the individual separated 
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compounds, and allows use of data-dependent MS/MS methods as well as spectral 
interpretation and metabolite identification software. The DESI-MS/MS and LC-MS/MS 
approaches, however, are complementary and can be utilized according to the requirements 
of the study. The TiO2 photocatalysis–DESI-MS rotating array platform is most suitable to 
applications where rapid and easy screening is needed instead of rigorous separation of 
possible isomeric products. 
 
 
Figure 13 Tentative structural assignment of the photocatalytic reaction products of buspirone 
(M+O and M+O-2H), verapamil (M-CH2, M-2xCH2 and M+O-2H), and amodiaquine 
(M+O) on a TiO2-coated glass wafer (see Table 1 for examples of the reactions). M-CH2 
product of verapamil ≥ 2 isomers: 1. O-demethylation of B ring and 2. O-demethylation of 
A-ring or N-demethylation (the alternative reaction sites are italicized). M-2xCH2 products 
of verapamil ≥ 2 isomers: 1. O-demethylation of B ring and O-demethylation of A-ring or 
N-demethylation, 2. O-demethylation of A-ring and N-demethylation or 2x O-demethylation 
of A-ring. 
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5 Conclusions and future perspectives 
Developing clever methods to investigate biologically relevant oxidation reactions is 
essential, as redox reactions play a major role in several physiological and 
pathophysiological processes such as oxidative stress, which causes oxidative damage to 
biological macromolecules, and drug metabolism. TiO2 photocatalysis is an interesting 
option for imitation of biological oxidation reactions, as it produces several oxidizing 
species enabling several oxidation mechanisms; hydroxyl radicals, superoxide, and singlet 
oxygen can be formed in TiO2 photocatalysis, making it a potential technique to study 
oxidative modifications of biological macromolecules caused by ROS that are also involved 
in oxidative stress. In CYP450-catalyzed oxidative drug metabolism, two common initiation 
mechanisms are hydrogen atom transfer and electron transfer from the substrate molecule 
to the enzyme. TiO2 photocatalysis enables both of these mechanisms, as hydroxyl radicals 
can abstract hydrogen atoms and holes on the TiO2 surface can accept electrons from the 
substrate. Direct electrochemical oxidation is limited to reactions beginning with single 
electron transfer, whereas the hydroxyl radical-based methods, such as EC-Fenton, enable 
only hydrogen atom abstraction or addition of hydroxyl radicals to unsaturated bonds. 
Furthermore, TiO2 photocatalysis is a nonhazardous oxidation method and easily accessible, 
as TiO2 particles and UV lamps are commercially available as well as relatively 
inexpensive. The photocatalytic reaction can be easily controlled by UV exposure time, and 
no other specific instrumentation is needed.   
In this work, TiO2 photocatalysis proved to be a feasible, fast, and simple method for 
oxidation of compounds with different polarities. TiO2 photocatalysis was, for the first time, 
used to study oxidation reactions of phosphorylated peptides. The hydroxyl radical-initiated 
oxidation resulted mainly in hydroxylation of nonphosphorylated tyrosine, whereas 
phosphorylation generally protected the tyrosine residue from oxidation. It should be 
assessed whether phosphorylation is involved in controlling oxidation of tyrosine residues 
in vivo, in order to open up new research targets. Other interesting applications concerning 
oxidation of biomolecules could be determination of the location of the double bond in 
unknown unsaturated lipids and oxidation of oligonucleotides. 
TiO2 photocatalysis imitated 44% and 31% of the phase I HLM metabolites of the model 
drugs and anabolic steroids, respectively, and performed better in imitation of phase I HLM 
metabolism than did EC-Fenton or direct EC. This can be explained by the mechanistic 
differences of the three imitation methods discussed above. All of the compared imitation 
methods produced too few metabolites and too many nonmetabolic products, and thus, none 
of them can be used for exact prediction of drug metabolites. The enzymatic reactions are 
highly selective and their diversity cannot be imitated adequately by a method with different 
selectivity, such as EC, or by relatively nonselective methods, such as TiO2 photocatalysis 
and EC-Fenton. For comparison, computational methods have been shown to correctly 
predict 50-90% of the most likely sites of metabolism,[168-172] and to rival the 
biotransformation experts in prediction accuracy.[168-169] Nevertheless, the in silico methods 
that predict metabolites instead of sites of metabolism tend to predict too many false 
metabolites because of the various combinations of metabolic reactions.[171-172] It seems 
unlikely that the in silico methods would completely abolish the need for in vitro and in vivo 
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metabolism experiments in the near future. It is noteworthy, however, that neither the in 
vitro metabolism experiments nor the animal experiments can exactly predict the human in 
vivo metabolism of a drug, yet these experiments provide other essential information, such 
as pharmacokinetic data, which cannot be derived from the imitation reactions. Even though 
the correlation of TiO2 photocatalytic products and the HLM metabolites was far from 
perfect, TiO2 photocatalysis may aid in compound optimization by revealing easily 
oxidizable spots in a drug molecule, which can potentially be metabolically susceptible sites 
as well.  
The imitation methods may provide straightforward approaches for rapid and low-cost 
synthesis of metabolite standards, obviating the need to develop multistep synthetic 
strategies or to purify compounds present in complex biological matrices, especially when 
these are not easily obtained by other methods. Nonetheless, fractionation is needed for 
purification of specific compounds, as a mixture of large number of compounds is usually 
obtained, particularly with TiO2 photocatalysis and EC-Fenton, which enable hydroxylation 
of various sites. TiO2 photocatalysis, being much faster than EC-Fenton or the enzymatic in 
vitro metabolism assays, can provide an extremely rapid and inexpensive way to produce 
aliphatic and aromatic hydroxylation products. Hence, an interesting use of TiO2 
photocatalysis, in addition to rapid synthesis of standards, could be diversification of hit or 
lead compounds, i.e. production of multiple hydroxylated derivatives of bioactive 
compounds, which may have improved activity, selectivity, or bioavailability relative to the 
original molecule. The preparative applications require scaling up, which should, however, 
be possible considering that TiO2 photocatalysis has been used for waste water treatment 
applications, where the volumes are large. EC has been widely used for studying reactive 
metabolites,[173] and glutathione conjugation of a reactive metabolite of paracetamol 
produced by TiO2 photocatalysis has also been demonstrated.[46] Thus, the wider 
applicability of TiO2 photocatalysis for studying reactive intermediates could be an 
interesting area for future research. 
Simple integration of TiO2 photocatalytic reactions into DESI-MS analysis by using the 
same TiO2-coated glass wafer as a sample platform for the photocatalysis and DESI-MS 
analysis omitted the need for the time-consuming removal of TiO2 particles prior to sample 
analysis and enhanced the speed of analysis considerably. Thus, the TiO2 photocatalysis–
DESI-MS rotating array platform enabled high-throughput screening of photocatalytic 
oxidation products as well as imitation of some drug metabolism reactions, even though the 
isomeric products could not be identified exactly. The major advantages of the TiO2 
photocatalysis–DESI-MS rotating array platform include straightforward fabrication, low 
sample consumption, and quick experiments to study biologically relevant oxidation 
reactions. The rotating platform can be further applied to investigate various catalytic 
reactions and combined with ambient mass spectrometric analysis using techniques other 
than DESI, e.g. direct analysis in real time, desorption atmospheric pressure 
photoionization, and various plasma-based techniques. The system could also be applied to 
photodegradation studies, with or without TiO2 coating, to support the study of 
photostability and environmental burden of drugs and other compounds. For instance, an 
analogous system, integrating an UV lamp above the DESI-MS spot, could enable online 
monitoring of photostability of solid drug formulations or active pharmaceutical 
ingredients. 
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In conclusion, TiO2 photocatalysis offers a rapid, inexpensive, and simple approach for 
oxidation of diverse compounds. With appropriate development in the future, the most 
feasible use of TiO2 photocatalysis in drug discovery and development is likely to be 
synthesis of metabolites or other more hydrophilic derivatives of bioactive compounds. 
However, probably a more interesting use of TiO2 photocatalysis is studying oxidation of 
various biomolecules. In addition, TiO2 photocatalysis may help in identification of 
environmental transformation products of drugs, pesticides, and other environmental 
pollutants and in their production for toxicity testing.  
 
 
64 
 
References 
[1] Butterfield, D.A., Lauderback, C.M., 2002. Lipid peroxidation and protein oxidation in 
Alzheimer's disease brain: Potential causes and consequences involving amyloid beta-
peptide-associated free radical oxidative stress. Free Radical Biol. Med. 32, 1050-1060. 
[2] Butterfield, D.A., Perluigi, M., Reed, T., Muharib, T., Hughes, C.P., Robinson, R.A.S., 
Sultana, R., 2012. Redox proteomics in selected neurodegenerative disorders: from its 
infancy to future applications. Antiox. Redox Signaling 17, 1610-1655. 
[3] Rani, V., Deep, G., Singh, R.K., Palle, K., Yadav, U.C.S., 2016. Oxidative stress and 
metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci. 148, 183-193. 
[4] Adibhatla, R.M., Hatcher, J.F., 2010. Lipid oxidation and peroxidation in CNS health 
and disease: from molecular mechanisms to therapeutic opportunities. Antiox. Redox 
Signaling 12, 125-169. 
[5] Reuter, S., Gupta, S.C., Chaturvedi, M.M., Aggarwal, B.B., 2010. Oxidative stress, 
inflammation, and cancer: How are they linked? Free Radical Biol. Med. 49, 1603-1616. 
[6] Guengerich, F.P., 2008. Cytochrome P450 and chemical toxicology. Chem. Res. 
Toxicol. 21, 70-83. 
[7] Rendic, S., Guengerich, F.P., 2012. Contributions of human enzymes in carcinogen 
metabolism. Chem. Res. Toxicol. 25, 1316-1383. 
[8] Davies, M.J., 2005. The oxidative environment and protein damage. Biochem. 
Biophys. Acta 1703, 93-109. 
[9] Pisoschi, A.M., Pop, A., 2015. The role of antioxidants in the chemistry of oxidative 
stress: A review. Eur. J. Med. Chem. 97, 55-74. 
[10] Sharma, V.K., Rokita, S.E., 2012. Wiley series of reactive intermediates in chemistry 
and biology: Oxidation of amino acids, peptides, and proteins: kinetics and mechanism. 
John Wiley & Sons, Somerset, NJ, USA. 
[11] Du, J., Gebicki, J.M., 2004. Proteins are major initial cell targets of hydroxyl free 
radicals. Int. J. Biochem. Cell Biol. 36, 2334-2343. 
[12] Feeney, M.B., Schöneich, C., 2012. Tyrosine modifications in aging. Antiox. Redox 
Signaling 17, 1571-1579. 
[13] Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., Raunio, H., 
2008. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. 
Toxicol. 82, 667-715. 
[14] Guengerich, F.P., 2001. Common and uncommon cytochrome P450 reactions related 
to metabolism and chemical toxicity. Chem. Res. Toxicol. 14, 611-650. 
 
 
65 
 
[15] Park, B.K., Boobis, A., Clarke, S., Goldring, C.E.P., Jones, D., Kenna, J.G., Lambert, 
C., Laverty, H.G., Naisbitt, D.J., Nelson, S., Nicoll-Griffith, D.A., Obach, R.S., 
Routledge, P., Smith, D.A., Tweedie, D.J., Vermeulen, N., Williams, D.P., Wilson, I.D., 
Baillie, T.A., 2011. Managing the challenge of chemically reactive metabolites in drug 
development. Nat. Rev. Drug Discovery 10, 292-306. 
[16] Guengerich, F.P., 2013. Kinetic deuterium isotope effects in cytochrome P450 
oxidation reactions. J. Labelled Compd. Radiopharm. 56, 428-431. 
[17] Pelkonen, O., Turpeinen, M., Uusitalo, J., Rautio, A., Raunio, H., 2005. Prediction of 
drug metabolism and interactions on the basis of in vitro investigations. Basic Clin. 
Pharmacol. Toxicol. 96, 167-175. 
[18] Gómez-Lechón, M., Donato, M., Castell, J., Jover, R., 2004. Human hepatocytes in 
primary culture: The choice to investigate drug metabolism in man. Curr. Drug Metab. 5, 
443-462. 
[19] Lohmann, W., Karst, U., 2008. Biomimetic modeling of oxidative drug metabolism. 
Anal. Bioanal Chem. 391, 79-96. 
[20] Pritchard, J.F., Jurima-Romet, M., Reimer, M.L.J., Mortimer, E., Rolfe, B., Cayen, 
M.N., 2003. Making better drugs: Decision gates in non-clinical drug development. Nat. 
Rev. Drug Discovery 2, 542-553. 
[21] Roeser, J., Bischoff, R., Bruins, A.P., Permentier, H.P., 2010. Oxidative protein 
labeling in mass-spectrometry-based proteomics. Anal. Bioanal. Chem. 397, 3441-3455. 
[22] Xu, G., Chance, M.R., 2007. Hydroxyl radical-mediated modification of proteins as 
probes for structural proteomics. Chem. Rev. 107, 3514-3543. 
[23] Permentier, H.P., Bruins, A.P., Bischoff, R., 2008. Electrochemistry-mass 
spectrometry in drug metabolism and protein research. Mini-Rev. Med. Chem. 8, 46-56. 
[24] Bernadou, J., Meunier, B., 2004. Biomimetic chemical catalysts in the oxidative 
activation of drugs. Adv. Synth. Catal. 346, 171-184. 
[25] Jurva, U., Wikström, H.V., Weidolf, L., Bruins, A.P., 2003. Comparison between 
electrochemistry/mass spectrometry and cytochrome P450 catalyzed oxidation reactions. 
Rapid Commun. Mass Spectrom. 17, 800-810. 
[26] Johansson, T., Weidolf, L., Jurva, U., 2007. Mimicry of phase I drug metabolism - 
novel methods for metabolite characterization and synthesis. Rapid Commun.Mass 
Spectrom. 21, 2323-2331. 
[27] Liang, S., Shiue, Y., Kuo, C., Guo, S., Liao, W., Tsai, E., 2013. Online monitoring 
oxidative products and metabolites of nicotine by free radicals generation with Fenton 
reaction in tandem mass spectrometry. Sci. World J. 2013, 189162. 
 
 
66 
 
[28] Van der Steen, J., Timmer, E.C., Westra, J.G., Benckhuysen, C., 1973. 4-
Hydroperoxidation in Fenton oxidation of antitumor agent cyclophosphamide. 
J.Am.Chem.Soc. 95, 7535-7536. 
[29] Zbaida, S., Kariv, R., Fischer, P., Silman-Greenspan, J., Tashma, Z., 1986. Reaction 
of cimetidine with Fenton reagent. Eur. J. Biochem. 154, 603-605. 
[30] Calza, P., Pazzi, M., Medana, C., Baiocchi, C., Pelizzetti, E., 2004. The 
photocatalytic process as a tool to identify metabolitic products formed from dopant 
substances: the case of buspirone. J. Pharm. Biomed. Anal. 35, 9-19. 
[31] Nissilä, T., Sainiemi, L., Karikko, M., Kemell, M., Ritala, M., Franssila, S., 
Kostiainen, R., Ketola, R.A., 2011. Integrated photocatalytic micropillar nanoreactor 
electrospray ionization chip for mimicking phase I metabolic reactions. Lab Chip 11, 
1470-1476. 
[32] Kugelmann, E., Albert, C.R., Bringmann, G., Holzgrabe, U., 2011. Fenton's 
oxidation: A tool for the investigation of potential drug metabolites. J. Pharm. Biomed. 
Anal. 54, 1047-1058. 
[33] Zbaida, S., Kariv, R., Fischer, P., Gilhar, D., 1987. Reactions of theophylline, 
theobromine and caffeine with Fenton reagent - Simulation of hepatic-metabolism. 
Xenobiotica 17, 617-621. 
[34] Oturan, M.A., Pinson, J., Oturan, N., Deprez, D., 1999. Hydroxylation of aromatic 
drugs by the electro-Fenton method. Formation and identification of the metabolites of 
Riluzole. New J. Chem. 23, 793-794. 
[35] Oturan, M.A., Pinson, J., Bizot, J., Deprez, D., Terlain, B., 1992. Reaction of 
inflammation inhibitors with chemically and electrochemically generated hydroxyl 
radicals. J. Electroanal. Chem. 334, 103-109. 
[36] Baumann, A., Lohmann, W., Schubert, B., Oberacher, H., Karst, U., 2009. Metabolic 
studies of tetrazepam based on electrochemical simulation in comparison to in vivo and in 
vitro methods. J. Chromatogr. A 1216, 3192-3198. 
[37] Gul, T., Bischoff, R., Permentier, H.P., 2017. Mechanism of aromatic hydroxylation 
of lidocaine at a Pt electrode under acidic conditions. Electrochim. Acta 224, 636-641. 
[38] Madsen, K.G., Skonberg, C., Jurva, U., Cornett, C., Hansen, S.H., Johansen, T.N., 
Olsen, J., 2008. Bioactivation of diclofenac in vitro and in vivo: Correlation to 
electrochemical studies. Chem. Res. Toxicol. 21, 1107-1119. 
[39] Bussy, U., Delaforge, M., El-Bekkali, C., Ferchaud-Roucher, V., Krempf, M., Tea, I., 
Galland, N., Jacquemin, D., Boujtita, M., 2013. Acebutolol and alprenolol metabolism 
predictions: comparative study of electrochemical and cytochrome P450-catalyzed 
reactions using liquid chromatography coupled to high-resolution mass spectrometry. 
Anal. Bioanal. Chem. 405, 6077-6085. 
 
 
67 
 
[40] van Leeuwen, S.M., Blankert, B., Kauffmann, J.M., Karst, U., 2005. Prediction of 
clozapine metabolism by on-line electrochemistry/liquid chromatography/mass 
spectrometry. Anal. Bioanal. Chem. 382, 742-750. 
[41] Jahn, S., Baumann, A., Roscher, J., Hense, K., Zazzeroni, R., Karst, U., 2011. 
Investigation of the biotransformation pathway of verapamil using electrochemistry/liquid 
chromatography/mass spectrometry - A comparative study with liver cell microsomes. J. 
Chromatogr. A 1218, 9210-9220. 
[42] Madsen, K.G., Olsen, J., Skonberg, C., Hansen, S.H., Jurva, U., 2007. Development 
and evaluation of an electrochemical method for studying reactive phase-I metabolites: 
Correlation to in vitro drug metabolism. Chem. Res. Toxicol. 20, 821-831. 
[43] Lassila, T., Mattila, S., Turpeinen, M., Tolonen, A., 2015. Glutathione trapping of 
reactive drug metabolites produced by biomimetic metalloporphyrin catalysts. Rapid 
Commun. Mass Spectrom. 29, 521-532. 
[44] Medana, C., Calza, P., Giancotti, V., Dal Bello, F., Pasello, E., Montana, M., 
Baiocchi, C., 2011. Horse metabolism and the photocatalytic process as a tool to identify 
metabolic products formed from dopant substances: the case of sildenafil. Drug Test. 
Anal. 3, 724-734. 
[45] Medana, C., Calza, P., Giancotti, V., Dal Bello, F., Aragno, M., Baiocchi, C., 2013. 
Study of the photocatalytic transformation of synephrine: a biogenic amine relevant in 
anti-doping analysis. Anal. Bioanal. Chem. 405, 1105-1113. 
[46] Raoof, H., Mielczarek, P., Michalow, K.A., Rekas, M., Silberring, J., 2013. Synthesis 
of metabolites of paracetamol and cocaine via photooxidation on TiO2 catalyzed by UV 
light. J. Photochem. Photobiol. B 118, 49-57. 
[47] Maleknia, S.D., Downard, K.M., 2014. Advances in radical probe mass spectrometry 
for protein footprinting in chemical biology applications. Chem. Soc. Rev. 43, 3244-3258. 
[48] Fenton, H.J.H., 1894. LXXIII.-Oxidation of tartaric acid in presence of iron. J. Chem. 
Soc., Trans. 65, 899–910.  
[49] Haber, V.F., Weiss, J., 1932. Über die Katalyse des Hydroxyperoxydes. 
Naturwissenschaften 20, 948–950. 
[50] Monroe, E.B., Heien, M.L., 2013. Electrochemical generation of hydroxyl radicals 
for examining protein structure. Anal. Chem. 85, 6185-6189. 
[51] Jurva, U., Wikström, H.V., Bruins, A.P., 2002. Electrochemically assisted Fenton 
reaction: reaction of hydroxyl radicals with xenobiotics followed by on-line analysis with 
high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. 
Mass Spectrom. 16, 1934-1940. 
 
 
68 
 
[52] Maleknia, S.D., Brenowitz, M., Chance, M.R., 1999. Millisecond radiolytic 
modification of peptides by synchrotron X-rays identified by mass spectrometry. Anal. 
Chem. 71, 3965-3973. 
[53] Maleknia, S.D., Kiselar, J.G., Downard, K.M., 2002. Hydroxyl radical probe of the 
surface of lysozyme by synchrotron radiolysis and mass spectrometry. Rapid Commun. 
Mass Spectrom. 16, 53-61. 
[54] Tong, X., Wren, J.C., Konermann, L., 2008. Gamma-ray-mediated oxidative labeling 
for detecting protein conformational changes by electrospray mass spectrometry. Anal. 
Chem. 80, 2222-2231. 
[55] Watson, C., Janik, I., Zhuang, T., Charvátová, O., Woods, R.J., Sharp, J.S., 2009. 
Pulsed electron beam water radiolysis for submicrosecond hydroxyl radical protein 
footprinting. Anal. Chem. 81, 2496-2505. 
[56] Zhang, H., Gau, B.C., Jones, L.M., Vidavsky, I., Gross, M.L., 2011. Fast 
photochemical oxidation of proteins for comparing structures of protein-ligand complexes: 
The calmodulin-peptide model system. Anal. Chem. 83, 311-318. 
[57] Maleknia, S.D., Chance, M.R., Downard, K.M., 1999. Electrospray-assisted 
modification of proteins: a radical probe of protein structure. Rapid Commun. Mass 
Spectrom. 13, 2352-2358. 
[58] Xu, G., Chance, M.R., 2005. Radiolytic modification and reactivity of amino acid 
residues serving as structural probes for protein footprinting. Anal. Chem. 77, 4549-4555. 
[59] Liu, F., Lai, S., Tong, H., Lakey, P.S.J., Shiraiwa, M., Weller, M.G., Pöschl, U., 
Kampf, C.J., 2017. Release of free amino acids upon oxidation of peptides and proteins by 
hydroxyl radicals. Anal. Bioanal. Chem. 409, 2411-2420. 
[60] Shum, W., Maleknia, S.D., Downard, K.M., 2005. Onset of oxidative damage in 
alpha-crystallin by radical probe mass-spectrometry. Anal. Biochem. 344, 247-256. 
[61] Baron, C.P., Refsgaard, H.H.F., Skibsted, L.H., Andersen, M.L., 2006. Oxidation of 
bovine serum albumin initiated by the Fenton reaction - effect of EDTA, tert-
butylhydroperoxide and tetrahydrofuran. Free Radic.Res. 40, 409-417. 
[62] Sharp, J.S., Becker, J.M., Hettich, R.L., 2003. Protein surface mapping by chemical 
oxidation: Structural analysis by mass spectrometry. Anal. Biochem. 313, 216-225. 
[63] Wong, J.W.H., Maleknia, S.D., Downard, K.M., 2005. Hydroxyl radical probe of the 
calmodulin-melittin complex interface by electrospray ionization mass spectrometry. J. 
Am. Soc. Mass Spectrom. 16, 225-233. 
[64] Leser, M., Pegan, J., El Makkaoui, M., Schlatterer, J.C., Khine, M., Law, M., 
Brenowitz, M., 2015. Protein footprinting by pyrite shrink-wrap laminate. Lab Chip 15, 
1646-1650. 
 
 
69 
 
[65] Bisby, R.H., Tabassum, N., 1988. Properties of the radicals formed by one-electron 
oxidation of acetaminophen—A pulse radiolysis study. Biochem. Pharmacol. 37, 2731-
2738. 
[66] Bisby, R.H., 1990. Reactions of a free radical intermediate in the oxidation of 
amodiaquine. Biochem. Pharmacol. 39, 2051-2055. 
[67] Ismail, F.M.D., Drew, M.G.B., Navaratnam, S., Bisby, R.H., 2009. A pulse radiolysis 
study of free radicals formed by one-electron oxidation of the antimalarial drug 
pyronaridine. Res. Chem. Intermed. 35, 363-377. 
[68] Bussy, U., Boujtita, M., 2014. Advances in the electrochemical simulation of 
oxidation reactions mediated by cytochrome P450. Chem. Res. Toxicol. 27, 1652-1668. 
[69] Permentier, H.P., Jurva, U., Barroso, B., Bruins, A.P., 2003. Electrochemical 
oxidation and cleavage of peptides analyzed with on-line mass spectrometric detection. 
Rapid Commun. Mass Spectrom. 17, 1585-1592. 
[70] Permentier, H.P., Bruins, A.P., 2004. Electrochemical oxidation and cleavage of 
proteins with on-line mass spectrometric detection: development of an instrumental 
alternative to enzymatic protein digestion. J. Am. Soc. Mass Spectrom. 15, 1707-1716. 
[71] Maleknia, S.D., Johnson, R., 2012. Mass Spectrometry of Amino Acids and Proteins. 
In: Hughes, A. (Ed.), Amino acids, peptides and proteinds in organic chemistry, Vol. 5: 
Analysis and function of amino acids and peptides. Wiley-VCH Verlag GmbH, 
Weinheim, Germany, pp. 1-50. 
[72] Kerman, K., Vestergaard, M., Chikae, M., Yamamura, S., Tamiya, E., 2007. Label-
free electrochemical detection of the phosphorylated and non-phosphorylated forms of 
peptides based on tyrosine oxidation. Electrochem. Commun. 9, 976-980. 
[73] Qu, N., Wan, B., Guo, L., 2008. Label-free electrochemical differentiation of 
phosphorylated and non-phosphorylated peptide by electro-catalyzed tyrosine oxidation. 
Analyst 133, 1246-1249. 
[74] Hunter, T., 2000. Signaling - 2000 and beyond. Cell 100, 113-127. 
[75] Nouri-Nigjeh, E., Bischoff, R., Bruins, A.P., Permentier, H.P., 2011. 
Electrochemistry in the mimicry of oxidative drug metabolism by cytochrome P450s. 
Curr. Drug Metab. 12, 359-371. 
[76] Lohmann, W., Karst, U., 2009. Electrochemistry meets enzymes: instrumental on-line 
simulation of oxidative and conjugative metabolism reactions of toremifene. Anal. 
Bioanal. Chem. 394, 1341-1348. 
[77] Jirásko, R., Mikysek, T., Chagovets, V., Vokřál, I., Holčapek, M., 2013. Structural 
characterization of electrochemically and in vitro biologically generated oxidation 
products of atorvastatin using UHPLC/MS/MS. Anal. Bioanal. Chem. 405, 7181-7193. 
 
 
70 
 
[78] Sono, M., Roach, M.P., Coulter, E.D., Dawson, J.H., 1996. Heme-containing 
oxygenases. Chem. Rev. 96, 2841-2888. 
[79] CarvalhoDa-Silva, D., Mac Leod, T.C.O., de Faria, A.L., dos Santos, J.S., Dai de 
Carvalho, M. E. M., Rebouças, J.S., Idemori, Y.M., das Dores Assis, M., 2011. 
Carbamazepine oxidation catalyzed by manganese porphyrins: Effects of the β-
bromination of the macrocycle and the choice of oxidant. Appl. Catal., A 408, 25-30. 
[80] Chauhan, S.M.S., Kandadai, S.A., Kumar, A., 2002. Biomimetic reduction of 
nimesulide with NaBH4 catalyzed by metalloporphyrins. Chem. Pharm. Bull. 50, 1421-
1422. 
[81] Balogh, G.T., Keseru, G.M., 2004. Metalloporphyrin mediated biomimetic 
oxidations. A useful tool for the investigation of cytochrome P450 catalyzed oxidative 
metabolism. Arkivoc, 124-139. 
[82] Othman, S., Mansuy-Mouries, V., Bensoussan, C., Battioni, P., Mansuy, D., 2000. 
Hydroxylation of diclofenac: an illustration of the complementary roles of biomimetic 
metalloporphyrin catalysts and yeasts expressing human cytochromes P450 in drug 
metabolism studies. C. R. Acad. Sci., Ser. IIc: Chim. 3, 751-755. 
[83] Bochot, C., Bartoli, J., Frapart, Y., Dansette, P.M., Mansuy, D., Battioni, P., 2007. 
Synthesis and spectroscopic, electrochemical, and catalytic properties of a new manganese 
porphyrin bearing four positive charges close to the metal. J. Mol. Catal. A: Chem. 263, 
200-205. 
[84] Chauhan, S.M.S., Kandadai, S.A., Sahoo, B., 2001. Regioselective biomimetic 
oxidation of etodolac with iodosylbenzene catalyzed by halogenated and perhalogenated 
metalloporphyrins in dichloromethane. Chem. Pharm. Bull. 49, 1375-1376. 
[85] Mac Leod, T.C.O., Faria, A.L., Barros, V.P., Queiroz, M.E.C., Assis, M.D., 2008. 
Primidone oxidation catalyzed by metalloporphyrins and Jacobsen catalyst. J. Mol. Catal. 
A: Chem. 296, 54-60. 
[86] Melo, A.J.B., Iamamoto, Y., Maestrin, A.P.J., Lindsay Smith, J.R., Santos, M.D., 
Lopes, N.P., Bonato, P.S., 2005. Biomimetic oxidation of praziquantel catalysed by 
metalloporphynins. J. Mol. Catal. A: Chem. 226, 23-31. 
[87] Neves, C.M.B., Simoes, M.M.Q., Domingues, M.R.M., Santos, I.C.M.S., Neves, 
M.G.P.M.S., Almeida Paz, F.A., Silva, A.M.S., Cavaleiro, J.A.S., 2012. Oxidation of 
diclofenac catalyzed by manganese porphyrins: synthesis of novel diclofenac derivatives. 
Rsc Advances 2, 7427-7438. 
[88] Breslow, R., Huang, Y., Zhang, X., Yang, J., 1997. An artificial cytochrome P450 
that hydroxylates unactivated carbons with regio- and stereoselectivity and useful catalytic 
turnovers. Proc. Natl. Acad. Sci. U. S. A. 94, 11156-11158. 
[89] Fang, Z., Breslow, R., 2006. Metal coordination-directed hydroxylation of steroids 
with a novel artificial P-450 catalyst. Org. Lett. 8, 251-254. 
 
 
71 
 
[90] Stuk, T.L., Grieco, P.A., Marsh, M.M., 1991. Site-selective hydroxylation of steroids 
via oxometalloporphinates covalently linked to ring-D: Introduction of hydroxyl-groups 
into the C(9) and C(12) position of 5α-androstanes. J. Org. Chem. 56, 2957-2959. 
[91] Yang, J., Breslow, R., 2000. Selective hydroxylation of a steroid at C-9 by an 
artificial cytochrome P-450. Angew. Chem. Int. Ed. Engl. 39, 2692-2694. 
[92] Akagah, B., Lormier, A.T., Fournet, A., Figadere, B., 2008. Oxidation of antiparasitic 
2-substituted quinolines using metalloporphyrin catalysts: scale-up of a biomimetic 
reaction for metabolite production of drug candidates. Org. Biomol. Chem. 6, 4494-4497. 
[93] HepatoChem Inc., http://www.hepatochem.com/ 2017. 
[94] Fujishima, A., Rao, T.N., Tryk, D.A., 2000. Titanium dioxide photocatalysis. J. 
Photochem. Photobiol. C: Photochem. Rev. 1, 1-21. 
[95] Luttrell, T., Halpegamage, S., Tao, J., Kramer, A., Sutter, E., Batzill, M., 2014. Why 
is anatase a better photocatalyst than rutile? - Model studies on epitaxial TiO2 films. Sci. 
Rep. 4, 4043. 
[96] Xu, M., Gao, Y., Moreno, E.M., Kunst, M., Muhler, M., Wang, Y., Idriss, H., Wöll, 
C., 2011. Photocatalytic activity of bulk TiO2 anatase and rutile single crystals using 
infrared absorption spectroscopy. Phys. Rev. Lett. 106, 138302. 
[97] Zhang, J., Zhou, P., Liu, J., Yu, J., 2014. New understanding of the difference of 
photocatalytic activity among anatase, rutile and brookite TiO2. Phys. Chem. Chem. Phys. 
16, 20382-20386. 
[98] Hurum, D.C., Agrios, A.G., Gray, K.A., Rajh, T., Thurnauer, M.C., 2003. Explaining 
the enhanced photocatalytic activity of Degussa P25 mixed-phase TiO2 using EPR. J. 
Phys. Chem. B 107, 4545-4549. 
[99] Fujishima, A., Zhang, X., Tryk, D.A., 2008. TiO2 photocatalysis and related surface 
phenomena. Surf. Sci. Rep. 63, 515-582. 
[100] Nosaka, Y., Daimon, T., Nosaka, A.Y., Murakami, Y., 2004. Singlet oxygen 
formation in photocatalytic TiO2 aqueous suspension. Phys. Chem. Chem. Phys. 6, 2917-
2918. 
[101] Daimon, T., Hirakawa, T., Kitazawa, M., Suetake, J., Nosaka, Y., 2008. Formation 
of singlet molecular oxygen associated with the formation of superoxide radicals in 
aqueous suspensions of TiO2 photocatalysts. Appl. Catal., A 340, 169-175. 
[102] Daimon, T., Nosaka, Y., 2007. Formation and behavior of singlet molecular oxygen 
in TiO2 photocatalysis studied by detection of near-infrared phosphorescence. J. Phys. 
Chem. C 111, 4420-4424. 
 
 
72 
 
[103] Daimon, T., Hirakawa, T., Nosaka, Y., 2008. Monitoring the formation and decay of 
singlet molecular oxygen in TiO2 photocatalytic systems and the reaction with organic 
molecules. Electrochemistry 76, 136-139. 
[104] Bhatkhande, D.S., Pangarkar, V.G., Beenackers, A.A.C.M., 2002. Photocatalytic 
degradation for environmental applications - a review. J. Chem. Tech. Biotech. 77, 102-
116. 
[105] Pelton, R., Geng, X., Brook, M., 2006. Photocatalytic paper from colloidal TiO2—
fact or fantasy. Adv. Colloid Interface Sci. 127, 43-53. 
[106] Larsen, M.R., Thingholm, T.E., Jensen, O.N., Roepstorff, P., Jørgensen, T.J.D., 
2005. Highly selective enrichment of phosphorylated peptides from peptide mixtures 
using titanium dioxide microcolumns. Mol. Cell. Proteomics 4, 873-886. 
[107] Liang, S., Makamba, H., Huang, S., Chen, S., 2006. Nano-titanium dioxide 
composites for the enrichment of phosphopeptides. J. Chromatogr. A 1116, 38-45. 
[108] Thingholm, T.E., Jørgensen, T.J.D., Jensen, O.N., Larsen, M.R., 2006. Highly 
selective enrichment of phosphorylated peptides using titanium dioxide. Nat. Protoc. 1, 
1929-1935. 
[109] Elsellami, L., Vocanson, F., Dappozze, F., Puzenat, E., Païsse, O., Houas, A., 
Guillard, C., 2010. Kinetic of adsorption and of photocatalytic degradation of 
phenylalanine effect of pH and light intensity. Appl. Catal., A 380, 142-148. 
[110] Yang, H., An, T., Li, G., Song, W., Cooper, W.J., Luo, H., Guo, X., 2010. 
Photocatalytic degradation kinetics and mechanism of environmental pharmaceuticals in 
aqueous suspension of TiO2: A case of β-blockers. J. Hazard. Mater. 179, 834-839. 
[111] Carrier, M., Perol, N., Herrmann, J., Bordes, C., Horikoshi, S., Paisse, J.O., Baudot, 
R., Guillard, C., 2006. Kinetics and reactional pathway of Imazapyr photocatalytic 
degradation Influence of pH and metallic ions. Appl. Catal., B 65, 11-20. 
[112] Sakkas, V.A., Calza, P., Medana, C., Villioti, A.E., Baiocchi, C., Pelizzetti, E., 
Albanis, T., 2007. Heterogeneous photocatalytic degradation of the pharmaceutical agent 
salbutamol in aqueous titanium dioxide suspensions. Appl. Catal., B 77, 135-144. 
[113] Jones, B.J., Vergne, M.J., Bunk, D.M., Locascio, L.E., Hayes, M.A., 2007. Cleavage 
of peptides and proteins using light-generated radicals from titanium dioxide. Anal. Chem. 
79, 1327-1332. 
[114] Antoniou, M.G., Shoemaker, J.A., De la Cruz, A.A., Dionysiou, D.D., 2008. 
Unveiling new degradation intermediates/pathways from the photocatalytic degradation of 
microcystin-LR. Environ. Sci. Technol. 42, 8877-8883. 
[115] Liu, I., Lawton, L.A., Robertson, P.K.J., 2003. Mechanistic studies of the 
photocatalytic oxidation of microcystin-LR: an investigation of byproducts of the 
decomposition process. Environ. Sci. Technol. 37, 3214-3219. 
 
 
73 
 
[116] Kostiainen, R., Kotiaho, T., Kuuranne, T., Auriola, S., 2003. Liquid 
chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism 
studies. J. Mass Spectrom. 38, 357-372. 
[117] Prasad, B., Garg, A., Takwani, H., Singh, S., 2011. Metabolite identification by 
liquid chromatography-mass spectrometry. TrAC, Trends Anal. Chem. 30, 360-387. 
[118] Chen, G., Pramanik, B.N., 2009. Application of LC/MS to proteomics studies: 
current status and future prospects. Drug Discov. Today 14, 465-471. 
[119] Han, X., Aslanian, A., Yates, J.R.III, 2008. Mass spectrometry for proteomics. Curr. 
Opin. Chem. Biol. 12, 483-490. 
[120] Zhu, M., Zhang, H., Humphreys, W.G., 2011. Drug metabolite profiling and 
identification by high-resolution mass spectrometry. J. Biol. Chem. 286, 25419-25425. 
[121] Marshall, A.G., Hendrickson, C.L., 2008. High-resolution mass spectrometers. 
Annu. Rev. Anal. Chem. 1, 579-599. 
[122] Maurer, H.H., Meyer, M.R., 2016. High-resolution mass spectrometry in toxicology: 
current status and future perspectives. Arch. Toxicol. 90, 2161-2172. 
[123] Rathahao-Paris, E., Alves, S., Junot, C., Tabet, J., 2016. High resolution mass 
spectrometry for structural identification of metabolites in metabolomics. Metabolomics 
12, 10. 
[124] Takamoto, K., Chance, M.R., 2006. Radiolytic protein footprinting with mass 
Spectrometry to probe the structure of macromolecular complexes. Annu. Rev. Biophys. 
Biomol. Struct. 35, 251-276. 
[125] Takáts, Z., Cotte-Rodriguez, I., Talaty, N., Chen, H., Cooks, R.G., 2005. Direct, 
trace level detection of explosives on ambient surfaces by desorption electrospray 
ionization mass spectrometry. Chem. Commun., 1950-1952. 
[126] Cody, R.B., Laramee, J.A., Durst, H.D., 2005. Versatile new ion source for the 
analysis of materials in open air under ambient conditions. Anal. Chem. 77, 2297-2302. 
[127] Takáts, Z., Wiseman, J.M., Gologan, B., Cooks, R.G., 2004. Mass spectrometry 
sampling under ambient conditions with desorption electrospray ionization. Science 306, 
471-473. 
[128] Haapala, M., Pol, J., Saarela, V., Arvola, V., Kotiaho, T., Ketola, R.A., Franssila, S., 
Kauppila, T.J., Kostiainen, R., 2007. Desorption atmospheric pressure photoionization. 
Anal. Chem. 79, 7867-7872. 
[129] Costa, A.B., Cooks, R.G., 2007. Simulation of atmospheric transport and droplet-
thin film collisions in desorption electrospray ionization. Chem. Commun., 3915-3917. 
 
 
74 
 
[130] Venter, A., Sojka, P.E., Cooks, R.G., 2006. Droplet dynamics and ionization 
mechanisms in desorption electrospray ionization mass spectrometry. Anal. Chem. 78, 
8549-8555. 
[131] Takáts, Z., Wiseman, J., Cooks, R.G., 2005. Ambient mass spectrometry using 
desorption electrospray ionization (DESI): instrumentation, mechanisms and applications 
in forensics, chemistry, and biology. J. Mass Spectrom. 40, 1261-1275. 
[132] Iribarne, J.V., Thomson, B.A., 1976. On the evaporation of small ions from charged 
droplets. J. Chem. Phys. 64, 2284-2294. 
[133] Thomson, B.A., Iribarne, J.V., 1979. Field induced ion evaporation from liquid 
surfaces at atmospheric pressure. J. Chem. Phys. 71, 4451-4463. 
[134] Dole, M., Mack, L.L., Hines, R.L., Mobley, R.C., Ferguson, L.D., Alice, M.B., 
1968. Molecular beams of macroions. J. Chem. Phys. 49, 2240-2249. 
[135] Li, X., 2013. Solvent effects and improvements in the deoxyribose degradation 
assay for hydroxyl radical-scavenging. Food Chem. 141, 2083-2088. 
[136] Wójcikowski, J., Pichard-Garcia, L., Maurel, P., Daniel, W.A., 2003. Contribution 
of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine 
neuroleptic promazine. Br. J. Pharmacol. 138, 1465-74. 
[137] Krauser, J.A., Voehler, M., Tseng, L., Schefer, A.B., Godejohann, M., Guengerich, 
F.P., 2004. Testosterone 1β-hydroxylation by human cytochrome P450 3A4. Eur. J. 
Biochem. 271, 3962-3969. 
[138] Choi, M.H., Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R., 2005. Characterization 
of testosterone 11β-hydroxylation catalyzed by human liver microsomal cytochromes 
P450. Drug Metab. Dispos. 33, 714-718. 
[139] Zhu, M., Zhao, W., Jimenez, H., Zhang, D., Yeola, S., Dai, R., Vachharajani, N., 
Mitroka, J., 2005. Cytochrome P450 3A-mediated metabolism of buspirone in human liver 
microsomes. Drug Metab. Dispos. 33, 500-507. 
[140] Zhang, H., Grubb, M., Wu, W., Josephs, J., Humphreys, W.G., 2009. Algorithm for 
thorough background subtraction of high-resolution LC/MS data: application to obtain 
clean product ion spectra from nonselective collision-induced dissociation experiments. 
Anal. Chem. 81, 2695-2700. 
[141] Li, A.C., Ding, J., Jiang, X., Denissen, J., 2009. Two-injection workflow for a liquid 
chromatography/LTQ-Orbitrap system to complete in vivo biotransformation 
characterization: demonstration with buspirone metabolite identification. Rapid Commun. 
Mass Spectrom. 23, 3003-3012. 
[142] Blankert, B., Hayen, H., van Leeuwen, S.M., Karst, U., Bodoki, E., Lotrean, S., 
Sandulescu, R., Diez, N.M., Dominguez, O., Arcos, J., Kauffmann, J.M., 2005. 
 
 
75 
 
Electrochemical, chemical and enzymatic oxidations of phenothiazines. Electroanalysis 
17, 1501-1510. 
[143] Bullock, P., Pearce, R., Draper, A., Podval, J., Bracken, W., Veltman, J., Thomas, 
P., Parkinson, A., 1995. Induction of liver microsomal cytochrome-P450 in cynomolgus 
monkeys. Drug Metab. Dispos. 23, 736-748. 
[144] Yamazaki, H., Shimada, T., 1997. Progesterone and testosterone hydroxylation by 
cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch. Biochem. 
Biophys. 346, 161-169. 
[145] Jung, B., Graf, H., Ullrich, V., 1985. A new monooxygenase product from 7-
ethoxycoumarin and its relation to the O-dealkylation reaction. Biol. Chem. Hoppe-Seyler 
366, 23-31. 
[146] Fisher, M.B., Jackson, D., Kaerner, A., Wrighton, S.A, Borel, A.G., 2002. 
Characterization by liquid chromatography-nuclear magnetic resonance spectroscopy and 
liquid chromatography-mass spectrometry of two coupled oxidative-conjugative metabolic 
pathways for 7-ethoxycoumarinin human liver microsomes treated with alamethicin. Drug 
Metab. Dispos. 30, 270-275. 
[147] Schänzer, W., 1996. Metabolism of anabolic androgenic steroids. Clin. Chem. 42, 
1001-1020. 
[148] Pozo, Ó.J., Van Eenoo, P., Deventer, K., Lootens, L., Van Thuyne, W., Parr, M.K., 
Schänzer, W., Sancho, J.V., Hernandez, F., Meuleman, P., Leroux-Roels, G., Delbeke, 
F.T., 2009. Detection and characterization of a new metabolite of 17 alpha-
methyltestosterone. Drug Metab. Dispos. 37, 2153-2162. 
[149] Massé, R., Ayotte, C., Bi, H., Dugal, R., 1989. Studies on anabolic-steroids III. 
Detection and characterization of stanozolol urinary metabolites in humans by gas-
chromatography mass-spectrometry. J. Chromatogr. B. Biomed. Appl. 497, 17-37. 
[150] Pozo, O.J., Van Eenoo, P., Deventer, K., Lootens, L., Grimalt, S., Sancho, J.V., 
Hernández, F., Meuleman, P., Leroux-Roels, G., Delbeke, F.T., 2009. Detection and 
structural investigation of metabolites of stanozolol in human urine by liquid 
chromatography tandem mass spectrometry. Steroids 74, 837-852. 
[151] Poelmans, S., De Wasch, K., De Brabander, H.F., Van de Wiele, M., Courtheyn, D., 
van Ginkel, L.A., Sterk, S.S., Delahaut, P., Dubois, M., Schilt, R., Nielen, M., 
Vercammen, J., Impens, S., Stephany, R., Hamoir, T., Pottie, G., Van Poucke, C., Van 
Peteghem, C., 2002. Analytical possibilities for the detection of stanozolol and its 
metabolites. Anal. Chim. Acta 473, 39-47. 
[152] Biddle, S.T.B., O'Donnell, A., Houghton, E., Creaser, C., 2009. Metabolism of 
methyltestosterone in the greyhound. Rapid Commun. Mass Spectrom. 23, 713-721. 
 
 
76 
 
[153] Blokland, M.H., van Rossum, H.J., Herbold, H.A., Sterk, S.S., Stephany, R.W., van 
Ginkel, L.A., 2005. Metabolism of methyltestosterone, norethandrolone and 
methylboldenone in a heifer. Anal. Chim. Acta 529, 317-323. 
[154] Roig, M., Segura, J., Ventura, R., 2007. Quantitation of 17 beta-nandrolone 
metabolites in boar and horse urine by gas chromatography-mass spectrometry. Anal. 
Chim. Acta 586, 184-195. 
[155] Scarth, J.P., Spencer, H.A., Hudson, S.C., Teale, P., Gray, B.P., Hillyer, L.L., 2010. 
The application of in vitro technologies to study the metabolism of the 
androgenic/anabolic steroid stanozolol in the equine. Steroids 75, 57-69. 
[156] Parr, M.K., Zöllner, A., Fußhöller, G., Opfermann, G., Schlörer, N., Zorio, M., 
Bureik, M., Schänzer, W., 2012. Unexpected contribution of cytochrome P450 enzymes 
CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination – Insights 
from metandienone metabolism. Toxicol. Lett. 213, 381-391. 
[157] Schänzer, W., Geyer, H., Donike, M., 1991. Metabolism of metandienone in man - 
Identification and synthesis of conjugated excreted urinary metabolites, determination of 
excretion rates and gas-chromatographic mass-spectrometric identification of bis-
hydroxylated metabolites. J. Steroid Biochem. Mol. Biol. 38, 441-464. 
[158] Wu, S., Zhang, K., Kaiser, N.K., Bruce, J.E.; Prior, D.C.; Anderson G.A., 2006. 
Incorporation of a flared inlet capillary tube on a Fourier transform ion cyclotron 
resonance mass spectrometer. J. Am. Soc. Mass Spectrom. 17, 772-779. 
[159] Da Costa, C., Reynolds, J.C., Whitmarsh, S., Lynch, T., Creaser, C.S., 2013. The 
quantitative surface analysis of an antioxidant additive in a lubricant oil matrix by 
desorption electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 
27, 2420-2424. 
[160] Gurdak, E., Green, F.M., Rakowska, P.D., Seah, M.P., Salter, T.L., Gilmore, I.S., 
2014. VAMAS interlaboratory study for desorption electrospray ionization mass 
spectrometry (DESI MS) intensity repeatability and constancy. Anal. Chem. 86, 9603-
9611. 
[161] Green, F.M., Stokes, P., Hopley, C., Seah, M.P., Gilmore, I.S., O'Connor, G., 2009. 
Developing repeatable measurements for reliable analysis of molecules at surfaces using 
desorption electrospray ionization. Anal. Chem. 81, 2286-2293. 
 [162] Churchill, F.C., Patchen, L.C, Campbell, C.C., Schwartz, I.K., Nguyen-Dinh, P., 
Dickinson, C.M., 1985. Amodiaquine as a prodrug - importance of metabolite(s) in the 
antimalarial effect of amodiaquine in humans. Life Sci. 36, 53-62.  
[163] Churchill, F.C.; Mount, D.L.; Patchen, L.C.; Björkman, A., 1986. Isolation, 
Characterization and Standardization of a Major Metabolite of Amodiaquine by 
Chromatographic and Spectroscopic Methods. J. Chromatogr. B. Biomed. Appl. 377, 307-
318.  
 
 
77 
 
[164] Johansson, T.; Jurva, U.; Grönberg, G.; Weidolf, L.; Masimirembwa, C., 2009. 
Novel Metabolites of Amodiaquine Formed by CYP1A1 and CYP1B1: Structure 
Elucidation Using Electrochemistry, Mass Spectrometry, and NMR. Drug Metab. Dispos. 
37, 571-579.  
[165] Li, X.; Björkman, A.; Andersson, T.B., Ridderström, M.; Masimirembwa, C., 2002. 
Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by 
CYP2C8: A new high affinity and turnover enzyme-specific probe substrate. J. 
Pharmacol. Exp. Ther. 300, 399–407. 
[166] Zhang, Y.; Vermeulen, N. P. E.; Commandeur, J. N. M., 2017. Characterization of 
human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite 
N-desethylamodiaquine. Br. J. Clin. Pharmacol. 83, 572-583. 
[167] Rousu, T., Herttuainen, J., Tolonen, A., 2010. Comparison of triple quadrupole, 
hybrid linear ion trap triple quadrupole, time-of-flight and LTQ-Orbitrap mass 
spectrometers in drug discovery phase metabolite screening and identification in vitro - 
amitriptyline and verapamil as model compounds. Rapid. Commun. Mass Spectrom. 24, 
939-957. 
[168] Campagna-Slater, V.; Pottel, J.; Therrien, E.; Cantin, L.; Moitessier, N., 2012. 
Development of a computational tool to rival experts in the prediction of sites of 
metabolism of xenobiotics by P450s. J. Chem Inf. Model. 52, 2471-2483. 
[169] Afzelius, L.; Hasselgren Arnby, C. ;Broo, A.; Carlsson, L.; Isaksson, C.; Jurva, U.; 
Kjellander, B.; Kolmodin, K.; Nilsson, K.; Raubacher, F.; Weidolf, L., 2007. State-of-the-
art tools for computational site of metabolism predictions: Comparative analysis, 
mechanistical insights, and future applications. Drug Metab. Rev. 39, 61-86. 
[170] Ford, K.A.; Ryslik, G.; Sodhi, J.; Halladay, J.; Diaz, D.; Dambach, D.; Masuda, M. 
2015. Computational predictions of the site of metabolism of cytochrome P450 2D6 
substrates: comparative analysis, molecular docking, bioactivation and toxicological 
implications. Drug Metab. Rev. 47, 291-319. 
[171] T'jollyn, H.; Boussery, K.; Mortishire-Smith, R.J.; Coe, K.; De Boeck, B.; Van 
Bocxlaer, J.F.; Mannens, G., 2011. Evaluation of three state-of-the-art metabolite 
prediction software packages (Meteor, MetaSite, and StarDrop) through independent and 
synergistic use. Drug Metab. Disposition, 39, 2066-2075 
[172] Meng, J.; Li, S.; Liu, X.; Zheng, M.; Li, H., 2017. RD-Metabolizer: an integrated 
and reaction types extensive approach to predict metabolic sites and metabolites of drug-
like molecules. Chem. Cent. J., 11, 65 
[173] Bussy, U., Boisseau, R., Thobie-Gautier, C., Boujtita, M., 2015. Electrochemistry-
mass spectrometry to study reactive drug metabolites and CYP450 simulations. TrAC, 
Trends Anal. Chem. 70, 67-73. 
 
